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Abstract 
Background: Eumycetoma lesion is well vascularized but the mechanisms involved in 
the control of angiogenesis in the lesion are poorly understood. In this study we 
investigated the role of hypoxia-inducible factor 1 (HIF-1), which regulates the 
transcription of a number of hypoxia-inducible genes, including those encoding vascular 
endothelial growth factor (VEGF) and adrenomedullin (ADM), and the role of fungal 
products in its induction. 
Material and Methods: HIF-1α protein expression in the lesion was assessed by 
counting positively immunocytochemically stained cells, using a monoclonal antibody 
against the α subunit (HIF-1α). In vivo expression of VEGF and ADM mRNA was 
assessed by quantitative real time reverse transcriptase- polymerase chain reaction (qRT-
PCR). In vitro induction of HIF-1 and its descendant genes was assessed in HepG2 cells 
treated with Madurella mycetomatis culture supernatants using Western blot analysis of 
HIF-1α and qRT-PCR analysis of VEGF an ADM mRNA. Secretion of VEGF protein by 
HepG2 cells treated with Madurella mycetomatis culture supernatants was assessed by 
ELISA. 
Results: Expression of HIF-1α protein was found to be upregulated in the fungal infested 
tissue (p = 0.003, n=23). The expression of both VEGF and ADM mRNA was evident in 
the fungal infested tissue (VEGF: p = 0.001, n=23; ADM: p < 0.001, n=23). Madurella 
mycetomatis strain 14 and strain 55 culture supernatants accummulate HIF-1α in HepG2 
cells and increased the expression of VEGF and ADM mRNA (strain 14: VEGF: p < 
0.001, ADM p < 0.001; strain 55: VEGF: p = 0.001, ADM: p = 0.003). VEGF secretion 
by HepG2 cells was increased under the effect of Madurella mycetomatis strain 14 
culture supernatants (p value = 0.003), an effect that was blunted by dexamethasone. 
 
xi 
Conclusion: This study concludes that HIF-1 and its down stream genes products, VEGF 
and ADM, are attendant in the development of the microcirculation in the mycetoma 
lesion caused by Madurella mycetomatis. The high concentration of HIF-1 in the lesion is 
in part due to increased transcription of HIF-1α mRNA and in part due to increased 
stability of HIF-1α. The stability of HIF-1α is at least partly due to a yet unidentified 
factor produced by Madurella mycetomatis. 
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
ﻇﻠﺖ اﻵﻟﻴﺎت اﻟﺘﻲ ﺗﺸﺎرك ﻓﻲ ﺿﺒﻂ ﻧﻤﻮ   ﺟﻴﺪ اﻟﻮﻋﺎﺋﻴﺔ و ﻟﻜﻦﻔﻄﺮياﻟﻮرم ﻓﺔ اﻟأﺛﺒﺘﺖ اﻟﺪراﺳﺎت اﻟﺴﺎﺑﻘﺔ أن ﺁ: ﺧﻠﻔﻴﺔ
 اﻷول  دور اﻟﻌﺎﻣﻞ ﻓﻲﺎﻟﺘﺤﻘﻴﻖﺑ  ﻗﻤﻨﺎﻓﻲ هﺬﻩ اﻟﺪراﺳﺔو .  ﻏﻴﺮ ﻣﻔﻬﻮﻣﺔﻔﻄﺮياﻟﻮرم اﻷوﻋﻴﺔ اﻟﺪﻣﻮﻳﺔ اﻟﺠﺪﻳﺪة ﻓﻲ ﺁﻓﺔ اﻟ
ﻟﺘﻲ ﺗﺸﻤﻞ ﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ و ا اﻷآﺴﺠﺔ  اﻟُﻤﺤﺜﺔ ﺑﻨﻘﺺاﻟﺬي ﻳﻨﻈﻢ اﻟﻨﺴﺦ ﻣﻦ ﻋﺪد ﻣﻦ اﻟﺠﻴﻨﺎت و ﻨﻘﺺ اﻷآﺴﺠﺔﺑ اﻟُﻤﺤﺚ
 و ﻨﻘﺺ اﻷآﺴﺠﺔﺑ  اﻷول اﻟُﻤﺤﺚاﻟﻌﺎﻣﻞاﻻوﻋﻴﺔ و اﻻدرﻳﻨﻮﻣﺪاﻟﻴﻦ آﻤﺎ ﻗﻤﻨﺎ ﺑﺎﻟﺘﺤﻘﻖ ﻓﻲ دور اﻟﻤﻨﺘﺠﺎت اﻟﻔﻄﺮﻳﺔ ﻓﻲ ﺣﺚ 
.ﻣﻨﺘﺠﺎت اﻟﺠﻴﻨﺎت اﻟﻮاﻗﻌﺔ ﺗﺤﺖ ﺳﻴﻄﺮﺗﻪ
د اﻟﺨﻼﻳﺎ اﻟﻤﻠﻄﺨﺔ  ﻋﻦ ﻃﺮﻳﻖ ﺗﻌﺪاﻨﻘﺺ اﻷآﺴﺠﺔﺑ  اﻷول اﻟُﻤﺤﺚﻠﻌﺎﻣﻞﺗﻢ ﺗﻘﻴﻴﻢ اﻟﺘﻌﺒﻴﺮ اﻟﺒﺮوﺗﻴﻨﻲ ﻟ: اﻟﻤﻮاد و اﻟﻮﺳﺎﺋﻞ
و ﻗﺪ إﺳﺘﺨﺪﻣﻨﺎ ﻓﻲ اﻟﺘﻠﻄﻴﺦ أﺟﺴﺎم ﻣﻨﺎﻋﻴﺔ ﻣﻀﺎدة اﺣﺎدﻳﺔ اﻟﻤﺼﺪر ﺿﺪ . إﻳﺠﺎﺑﻴﺎ ﺑﻌﺪ اﻟﺘﻠﻄﻴﺦ اﻟﻤﻨﺎﻋﻲ اﻟﻜﻴﻤﻴﺎﺋﻲ ﻟﻠﻨﺴﻴﺞ
آﻤﺎ ﻗﻤﻨﺎ ﺑﺘﻘﻴﻴﻢ اﻟﺘﻌﺒﻴﺮ اﻟﺤﻲ ﻟﻌﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔ و . ﻨﻘﺺ اﻷآﺴﺠﺔﺑ  اﻷول اﻟُﻤﺤﺚﻠﻌﺎﻣﻞاﻟﻮﺣﺪة اﻟﻔﺎ ﻟ
.  ﺑﻌﺪ ﺗﻔﺎﻋﻞ إﻧﺰﻳﻢ اﻟﻨﺴﺦ اﻟﻌﻜﺴﻲﻠﺘﻔﺎﻋﻞ اﻟﻤﺘﺴﻠﺴﻞ ﻟﻠﺒﻮﻟﻴﻤﻴﺮاتﻞ اﻟﻜﻤﻲ ﻟﻠﻮﻗﺖ اﻟﻮاﻗﻌﻲ ﻟاﻻدرﻳﻨﻮﻣﺪاﻟﻴﻦ ﺑﺈﺳﺘﺨﺪام اﻟﺘﺤﻠﻴ
 و ﻣﻨﺘﺠﺎت اﻟﺠﻴﻨﺎت اﻟﻮاﻗﻌﺔ ﺗﺤﺖ ﺳﻴﻄﺮﺗﻪ ﻓﻲ اﻟﻤﺨﺘﺒﺮ ﻓﻘﺪ ﺗﻢ ﻨﻘﺺ اﻷآﺴﺠﺔﺑ  اﻷول اﻟُﻤﺤﺚاﻟﻌﺎﻣﻞأﻣﺎ اﻟﺘﻌﺒﻴﺮ ﻋﻦ 
ﺎ ﺑﺄﺿﺎﻓﺔ اﻟﺴﺎﺋﻞ اﻟﻄﺎﻓﻲ ﻓﻮق ﻣﺰرﻋﺔ  ﻟﻠﺨﻼﻳﺎ اﻟﺴﺮﻃﺎﻧﻴﺔ اﻟﻜﺒﺪﻳﺔ ﺑﻌﺪ ﻣﻌﺎﻟﺠﺘﻬ2ﺗﻘﻴﻤﻬﺎ ﻓﻲ ﻣﺰارع ﻟﺨﻼﻳﺎ ﻣﻦ اﻟﺴﻼﻟﺔ 
 ﺑﺈﺳﺘﺨﺪام اﺳﻠﻮب اﻟﻠﻄﺦ ﻨﻘﺺ اﻷآﺴﺠﺔﺑ  اﻷول اﻟُﻤﺤﺚاﻟﻌﺎﻣﻞ و ﻣﻦ ﺛﻢ ﻗﻤﻨﺎ ﺑﺘﻘﻴﻴﻢ ﻣﺴﺘﻮى اﻟﻤﺎﻳﺴﺘﻮﻣﻴﺔﻟﻠﻤﺎدورﻳﻼ 
 اﻟﻤﺮﺳﻞ ﻟﺠﻴﻨﺎت ﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔ و اﻻدرﻳﻨﻮﻣﺪاﻟﻴﻦ ﻋﻦ اﻟﺤﻤﺾ اﻟﺮﻳﺒﻲ اﻟﻨﻮوياﻟﻐﺮﺑﻲ و ﺗﻘﻴﻴﻢ اﻟﺘﻌﺒﻴﺮ ﻋﻦ 
 ﺑﻌﺪ ﺗﻔﺎﻋﻞ إﻧﺰﻳﻢ اﻟﻨﺴﺦ اﻟﻌﻜﺴﻲ آﻤﺎ ﻗﻤﻨﺎ اﻳﻀًﺎ ﻠﺘﻔﺎﻋﻞ اﻟﻤﺘﺴﻠﺴﻞ ﻟﻠﺒﻮﻟﻴﻤﻴﺮاتﻲ ﻟﻠﻮﻗﺖ اﻟﻮاﻗﻌﻲ ﻟﻃﺮﻳﻖ اﻟﺘﺤﻠﻴﻞ اﻟﻜﻤ
 ﻟﻠﺨﻼﻳﺎ 2ﺑﺘﻘﻴﻴﻢ إﻓﺮاز ﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔ ﺑﻘﻴﺎس ﻣﺴﺘﻮاﻩ ﻓﻲ اﻟﺴﺎﺋﻞ اﻟﻄﺎﻓﻲ ﻓﻮق ﻣﺰرﻋﺔ ﺧﻼﻳﺎ ﻣﻦ اﻟﺴﻼﻟﺔ 
. ﺑﺎﻷﻧﺰﻳﻢ اﻟﻤﻨﺎﻋﻲ اﻟﻤﺮﺗﺒﻂ اﻟﺘﺸﺮبﺗﺤﻠﻴﻞاﻟﺴﺮﻃﺎﻧﻴﺔ اﻟﻜﺒﺪﻳﺔ ﻋﻦ ﻃﺮﻳﻖ 
ﻨﻘﺺ ﺑ  اﻷول اﻟُﻤﺤﺚاﻟﻌﺎﻣﻞوﺟﺪﻧﺎ ﻓﻲ هﺬﻩ اﻟﺪراﺳﻴﺔ أن هﻨﺎﻟﻚ أرﺗﻔﺎع ﻓﻲ ﻣﺴﺘﻮي اﻟﻔﺮﻋﻴﺔ اﻟﻔﺎ ﻟﺒﺮوﺗﻴﻦ : اﻟﻨﺘﺎﺋﺞ
 100.0= ع ) اﻟﻤﺮﺳﻞ ﻟﺠﻴﻨﺎت ﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔاﻟﺤﻤﺾ اﻟﺮﻳﺒﻲ اﻟﻨﻮوي و (32=  ، ن 300.0= ع ) اﻷآﺴﺠﺔ
آﻤﺎ وﺟﺪﻧﺎ أن اﻟﺴﺎﺋﻞ اﻟﻄﺎﻓﻲ ﻓﻮق . اﻟﻮرم اﻟﻔﻄﺮي ﻓﻲ ﺁﻓﺔ (32=  ، ن 300.0 >ع ) و اﻻدرﻳﻨﻮﻣﺪاﻟﻴﻦ (32= ، ن 
  اﻷول اﻟُﻤﺤﺚاﻟﻌﺎﻣﻞﻳﺴﺒﺐ  ارﺗﻔﺎﻋًﺎ ﻣﻠﺤﻮﻇًﺎ ﻓﻲ ﻣﺴﺘﻮي  اﻟﻤﺎﻳﺴﺘﻮﻣﻴﺔ  ﻣﻦ اﻟﻤﺎدورﻳﻼ55 و  41ﻣﺰرﻋﺔ اﻟﺴﻼﻻت 
 >ع ) اﻟﻤﺮﺳﻞ ﻟﺠﻴﻨﺎت ﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔ اﻟﺤﻤﺾ اﻟﺮﻳﺒﻲ اﻟﻨﻮوي و زﻳﺎدة ﻓﻲ اﻟﺘﻌﺒﻴﺮ ﻋﻦ ﻨﻘﺺ اﻷآﺴﺠﺔﺑ
 ﻟﻠﺴﻼﻟﺔ 100.0=  و ع 41 ﻟﻠﺴﻼﻟﺔ 100.0 >ع ) و اﻻدرﻳﻨﻮﻣﺪاﻟﻴﻦ (55 ﻟﻠﺴﻼﻟﺔ 100.0=  و ع 41ﺔ  ﻟﻠﺴﻼﻟ100.0
 41آﻤﺎ وﺟﺪﻧﺎ أن إﻓﺮاز ﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔ ﻳﺰداد ﺗﺤﺖ ﺗﺄﺛﻴﺮ اﻟﺴﺎﺋﻞ اﻟﻄﺎﻓﻲ ﻓﻮق ﻣﺰرﻋﺔ اﻟﺴﻼﻟﺔ . (55
.و هﺬا اﻷﺛﺮ ﻳﺨﺘﻔﻲ ﻋﻨﺪ اﻟﻤﻌﺎﻟﺠﺔ ﺑﺎﻟﺪﻳﻜﺴﺎﻣﻴﺜﺎزون( 300.0= ع  )اﻟﻤﺎﻳﺴﺘﻮﻣﻴﺔﻟﻠﻤﺎدورﻳﻼ 
,  و ﻣﻨﺘﻮﺟﺎت اﻟﺠﻴﻨﺎت اﻟﺘﻲ ﻳﺘﺤﻜﻢ ﻓﻴﻬﺎﻨﻘﺺ اﻷآﺴﺠﺔﺑ  اﻷول اﻟُﻤﺤﺚاﻟﻌﺎﻣﻞ اﻟﺪراﺳﺔ ﺗﺨﻠﺺ إﻟﻰ أنهﺬﻩ : اﻟﺨﻼﺻﺔ
 ﺗﺴﺒﺒﻪ  اﻟﺬي وﻋﺎﺋﻴﺔ ﺁﻓﺔ اﻟﻮرم اﻟﻔﻄﺮي ﻧﻤﻮ ﻓﻲﻣﻮﺟﻮدون ﺑﺪور ﻓﺎﻋﻞ,  و اﻻدرﻳﻨﻮﻣﺪاﻟﻴﻦﻋﺎﻣﻞ ﻧﻤﻮ ﺑﻄﺎﻧﺔ اﻻوﻋﻴﺔ
اﻟﺤﻤﺾ اﻟﺘﻌﺒﻴﺮ ﻋﻦ اﻟﺘﺮآﻴﺰ اﻟﻌﺎﻟﻲ ﻟﻠﻌﺎﻣﻞ اﻟﻤﺤﺚ ﺑﻨﻘﺺ اﻷآﺴﺠﺔ ﻳﺮﺟﻊ ﺟﺰﺋﻴًﺎ إﻟﻰ زﻳﺎدة . اﻟﻤﺎﻳﺴﺘﻮﻣﻴﺔاﻟﻤﺎدﻳﻮرﻳﻼ 
ة اﻟﻔﺎ ﻮﺣﺪاﻟ و ﺟﺰﺋﻴًﺎ ﻟﺰﻳﺎدة اﺳﺘﻘﺮار ﻟﺠﻴﻦ ة اﻟﻔﺎ ﻟﻠﻌﺎﻣﻞ اﻟﻤﺤﺚ ﺑﻨﻘﺺ اﻷآﺴﺠﺔﻟﻮﺣﺪا  اﻟﻤﺮﺳﻞ ﻟﺠﻴﻦاﻟﺮﻳﺒﻲ اﻟﻨﻮوي
 ة اﻟﻔﺎ ﻟﻠﻌﺎﻣﻞ اﻟﻤﺤﺚ ﺑﻨﻘﺺ اﻷآﺴﺠﺔ ﻳﻌﻮدﻮﺣﺪاﻟاﺳﺘﻘﺮار  اﻟﺪراﺳﺔ إﻟﻰ أن هﺬﻩآﻤﺎ ﺗﺸﻴﺮ . ﻟﻠﻌﺎﻣﻞ اﻟﻤﺤﺚ ﺑﻨﻘﺺ اﻷآﺴﺠﺔ
.اﻟﻤﺎﻳﺴﺘﻮﻣﻴﺔ اﻟﻤﺎدورﻳﻼﻋﻠﻰ اﻷﻗﻞ ﺟﺰﺋﻴﺎ ﻧﺘﻴﺠﺔ ﻟﻌﻮاﻣﻞ ﻟﻢ ﺗﺤﺪد ﺑﻌﺪ ﺗﻨﺘﺠﻬﺎ 
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Chapter One 
Introduction 
1:. INTRODUCTION 
1.1. Cellular Response to Hypoxia: Role of Hypoxia Inducible Factor-1 
(HIF-1) 
Oxygen is required by most living cells to generate adequate amounts of energy 
necessary for metabolic activities. Hypoxia, or oxygen deprivation, occurs within cells 
due to a variety of conditions. Depending on the severity, metabolic demise from 
insufficient oxygen may produce permanent cell damage as a result of hypoxic cell 
injury1. However, hypoxia can also play an important and beneficial physiologic and 
developmental role. It is integral for proper mammalian embryonic development and 
mediate a crucial developmental mechanisms including: closure of the neural tube, 
apoptosis, and proper morphological development during gestation2, 3. 
All organisms, from bacteria to humans, have evolved adaptive mechanisms to maintain 
oxygen homeostasis that are indispensable for their survival4. All nucleated cells in the 
human body sense oxygen concentration and respond to reduced oxygen availability 
(hypoxia) that is either acute or chronic in duration. As in other physiological systems, 
adaptive responses to acute hypoxia are mainly attributable to alterations of pre-existing 
proteins (e.g., by phosphorylation or changes in the redox state), whereas chronic changes 
in oxygen concentration principally occur as a result of alterations in gene expression1. 
Among the first gene products that are stimulated to over express at the onset of hypoxia 
is hypoxia inducible factor-1 (HIF-1) which is the master switch orchestrating the cellular 
response to hypoxia 5, 6, 7. HIF-1 was identified to mediate homeostatic responses to 
hypoxia by regulating over a hundred of genes. HIF-1 influence the expression of an 
array genes involved in metabolic adaptation, erythropoiesis, angiogenesis and vascular 
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tone, cell growth and differentiation, survival and apoptosis, and thus HIF-1 is a critical 
factor in development, physiology and disease8, 9. 
1.1.1. Biochemical properties of HIF-1 
HIF-1 is a heterodimer composed of two subunits: a 120-kDa HIFR-1α subunit and a 91-
94 kDa HIF-1β, both of which are members of the basic helix-loop-helix (bHLH) per-
arnt-sim (PAS) family10, 11, 12. Accordingly, HIF-1α and HIF-1β each contain a bHLH 
domain near the N terminus. There are two transcriptional activation domains in HIF-1α; 
one is referred to as amino-terminal transactivation domain (NAD), and the other as 
carboxy-terminal transactivation domain (CAD)13, 14, 15. In contrast, HIF-1β is identical to 
the previously discovered vertebrate protein, aryl hydrocarbon receptor nuclear 
translocator (ARNT) and it contains only one transcriptional activation domain (TAD) at 
the C terminus, which is unnecessary for HIF-1 complex function.16, 17  Furthermore, 
HIF-1α possesses a unique oxygen-dependent degradation domain (ODD) that critically 
controls protein stability18. The ODD overlaps with the NAD14 
1.1.2. Oxygen Dependent Regulation of HIF-1 
The activities of both the NAD and CAD of HIF-1 are enhanced by hypoxia. Since the 
NAD overlaps with the ODD its increase in transcriptional activity at hypoxia is largely 
attributed to increased protein stability. However, the increase in transcriptional activity 
of the CAD is not attributed to changes in protein level7.  Instead, hypoxia promotes the 
interaction of CAD with the transactivator protein cAMP-response-element-binding 
protein (CREB) binding protein (CBP/p300)19,20. Therefore, hypoxia regulates both HIF-
1α stability and transcriptional potency21. 
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1.1.2.1. HIF-1α  Degradation 
HIF-1α and HIF-1β are both constitutively expressed inside the cells. But under normoxic 
conditions, HIF-1α is subjected to proteasomal degradation through the ubiquitin-
proteasome pathway, which specifically targets the ODD of HIF-1α18, 22. Its half-life is 
less than 1 minute under normoxia23. HIF-1α degradation requires binding of von Hippel-
Lindau (VHL), which, in a complex with elongin B, elongin C24, 25, 26, and Cul227, acts as 
an E3 ubiquitin ligase for HIF-1α polyubiquitination28 by targeting the ODD29,30, 31. 
Oxygen-dependent hydroxylation of HIF-1α Pro564 enables specific binding to VHL32, 33, 
34. VHL independently also binds to hydroxylated Pro-402 of HIF-1α35. The HIF-1α -
VHL interaction strictly requires hydroxylation33. Hydroxylation of both prolines is 
catalyzed by a family of prolyl-4-hydroxylases (PHD) that belong to the 2-oxoglutarate-
dependent oxygenase superfamily36, 37, 38. Enzymatic activity of PHD is inhibited by 
hypoxia39, iron chelation33, transition metals40, and the 2-oxoglutarate analog N-
oxalylglycine41. Distinct inhibitors of prolyl hydroxylation, such as L-mimosine (L-
Mim), ethyl 3,4-dihydroxybenzoate (3,4-DHB), and 6-chlor-3-hydroxychinolin-2-
carbonic acid-N-carboxymethylamid (S956711), are capable of inducing HIFα and HIF 
target genes in vitro and in vivo and induce adaptive responses to hypoxia, including 
angiogenesis42.  
The tumor suppressor gene, p53, is also involved in the ubiquitination of HIF-1α, It 
promotes Mdm2-mediated ubiquitination and proteasomal degradation of HIF-1α43. The 
DNA-binding domain of p53 interacts in vitro with HIF-1α regions around Pro-402 and 
Pro-564 regardless of their hydroxylation, which may account for p53-mediated HIF-1α 
degradation in normoxia as well as hypoxia44. Consequently, HIF-1α degradation.is 
 
3 
inhibited by Jab1, a component of COP9 signalosome complex that targets p53 for 
degradation45. 
Under hypoxic conditions, HIF-1α is not marked for degradation and its concentration 
increases exponentially as cellular oxygen concentration is decreased from 20% to 0.5% 
as shown in Figure 1. It is revealed that oxygen concentrations in most tissue under 
normal physiologic conditions are in the range of 2 to 5%, indicating that any decrease in 
tissue oxygenation would occur along the steep portion of the HIF-1 response curve46. 
The stable HIF-1α dimerizes with constitutively expressed HIF-1β in the nucleus. to form 
HIF-147. The active HIF-1 heterodimer binds to cognate promoter elements and drives 
expression of HIF-1 target genes48.  
1.1.2.2. HIF-1α Transcriptional Activation 
Activation of HIF-responsive genes requires recruitment of a transcriptional coactivator 
such as p300, CBP, or SRC-1.15, 19, 49, 50 CBP and p300 are paralogous, multidomain 
proteins that serve as transcriptional coactivators by binding the transactivation domains 
of a vast array of transcription factors and by binding components of the general 
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transcriptional apparatus51. In addition, they have histone acetyltransferase (HAT) 
activity52. 
The C-terminal transactivation domain (CAD) of HIF-1α binds the CH1 domain of 
p30013, 14, 15, 20. Structural studies show that unbound CAD is intrinsically disordered and 
that the CH1 domain serves as a scaffold for CAD folding through extensive hydrophobic 
and polar interactions53, 54. The CAD per se is stable, but its transcriptional activity is 
hypoxia-inducible. This response is, at least in part, attributable to hypoxia-induced 
p300/CBP binding, which is governed by hydroxylation of asparagine-803 in HIF-1α55. 
The asparaginyl hydroxylation is catalyzed by another ferrous and oxygen-dependent 
enzyme56, FIH-1, which interacts with the C-terminal HIF-1α and represses HIF-1α 
transcriptional activity. Thus, in normoxia hydroxylated Asn-803 prevents p300/CBP 
binding, whereas hypoxia inhibits the activity of asparaginyl hydroxylase, thereby 
enhancing p300/CBP interaction and up-regulating target gene expression57. 
1.1.3. Oxygen Independent Regulation of HIF-1 
Apart from oxygen availability HIF-1α activity is regulated by oxygen independent 
factors including transitional metals, nitric oxide, reactive oxygen species, growth factors, 
and mechanical stress58. 
1.1.3.1. Transitional Metals and Iron Chelating Agents 
Transitional metal ions, such as cobalt, nickel, and zinc, and iron chelation stabilize HIF-
1α under normoxic conditions, and induce HIF-1 activity and downstream hypoxia 
inducible genes59, 60, 61. Transitional metal ions, which compete with iron for binding to 
the prolyl hydroxylase, and iron chelation, which binds available iron, act as prolyl 
hydroxylase inhibitors and prevent prolyl hydroxylation and ubiquitination of HIF-1α62. 
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1.1.3.2. Nitric Oxide (NO) 
The effect of NO on HIF-1α is controversial. It was shown that NO at relatively high 
concentration reduces the hypoxic induction of HIF-163, 64, 65 and represses its 
transcriptional activity66. However, it was demonstrated later that NO under different 
conditions could induce the accumulation of HIF-1α even under normoxic conditions67, 68, 
69, 70, 71. The effect of NO on HIF-1 seems to be dependent on NO concentration72, the 
chemical structure of NO doner73, and the time of application74. 
1.1.3.3. Reactive Oxygen Species (ROS) 
Studies have shown that alterations in the levels of reactive oxygen species (ROS) 
provide a redox signal for HIF-1 induction by hypoxia75, 76. Interestingly, ROS also 
appear to regulate HIF-1 activity under normoxia. In some cell types, increased ROS 
production has been shown to mediate HIF-1α protein accumulation and HIF-1-
dependent transcription by hormones, growth factors, and transition metals76, 77, 78. 
Moreover, direct exposure of cells to ROS may also induce HIF-1α protein levels and 
downstream hypoxia inducible genes transcription77, 79. 
1.1.3.4. Growth Factors and Cytokines 
The growth factor dependent expression of HIF-1α was first demonstrated in prostate 
cancer cells, in which HIF-1α is constitutively expressed even under normoxic 
conditions80. Growth factors reported to elicit such effect include insulin81, insulinlike 
growth factor81,82, epidermal growth factor83, and interleukin-184, 85, 86. interleukin-487, 
interleukin-1888, tumor necrosis factor-α (TNF-α) 68, 89. In contrast to regulation via the 
ubiquitinproteasome pathway, growth factors and cytokines stimulate HIF-1α  synthesis 
by inducing phosphorylation of translational regulatory proteins90, 91, 92. They stimulate 
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their receptors and activate the receptor tyrosine kinases, and in turn sequentially activate 
PI3K, a serine/thereonine kinase AKT/PKB, and FKBP rapamycin associated protein 
(FRAP), finally, the FRAP stimulates the expression of HIF-1α under normoxic 
conditions83. 
1.1.3.5. Mechanical Stress 
Mechanical stretch activates the gene expression of HIF-1α in the non-ischemic 
myocardium93 and vascular smooth muscle cells94. This mechanical effect is possibly 
mediated by the p42/p44 mitogen-activated protein kinase (MAPK) pathway95. Since the 
stretch mediated induction of HIF-1α can be suppressed by gadolinium, a stretch-
activated channel (SAC) inhibitor, SACs have been proposed as candidate 
mechanotransducers involved in the stretch-mediated activation of HIF-1α94. These 
findings suggest that HIF-1α plays an important role in the adaptation of the myocardium 
to mechanical stresses94. 
1.1.4. HIF-1 target genes 
Many processes involved in oxygen homeostasis are mediated by HIF-1, which regulates 
the expression of over a hundred of target genes (Table 2). Thus, HIF-1 represents the 
link between oxygen sensors and effectors at the cellular, local, and systemic level. To 
activate transcription of target genes, HIF-1 binds DNA at sites represented by the 
consensus sequence 5′-RCGTG-3′82. The HIF-1 binding site is present within a hypoxia 
response element (HRE), a cis-acting transcriptional regulatory sequence that can be 
located within 5′-flanking, 3′-flanking, or intervening sequences of target genes96, 97. The 
presence of an intact HIF-1 binding site is necessary, but not sufficient, for mediation of 
transcriptional activation98, 99. The number of target genes activated by HIF-1 continues 
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to increase and includes genes whose protein products are involved in erythropoiesis, 
angiogenesis, vascular remodeling, vasomotor responses energy metabolism, and cell 
proliferation and viability. 
1.1.4.1. HIF-1 target genes involved in iron metabolism and erythropoiesis 
Among the first genes discovered to be HIF-1 dependent is erythropoietin gene5 which 
plays a key role in O2 homeostasis by regulating blood O2-carrying capacity. Iron is 
required for heme formation and is the most common limiting factor in erythropoiesis. 
Hypoxia was found to increase the expression of transferrin, probably to enhance the iron 
transport to erythroid tissues100. The transferrin receptor is a hypoxia-inducible HIF-1 
target gene, enabling cellular transferrin uptake101, 102, Ceruloplasmin was also shown to 
be a HIF-1 target gene103. Ceruloplasmin, also known as a ferroxidase, is required to 
oxidize ferrous to ferric iron. Because only ferric iron can be bound by transferrin, 
hypoxic ceruloplasmin induction is likely to support iron supply to erythroid tissues. 
Finally, HIF-1 also upregulates the erythroid-specific isoform of 5-aminolevulinate 
synthase (ALAS2) 104, which catalyzes the rate-limiting step in heme biosynthesis 
1.1.4.2. HIF-1 target genes involved in vascular biology 
The vascular system underlies tight oxygen-regulated control. Vascular endothelial 
growth factor (VEGF)105, 106, 107 and its receptor Flt-1107 are the most prominent HIF-1 
target genes involved in vascular biology. HIF-1 also regulates plasminogen activator 
inhibitor 1108, which is involved in vascular remodeling, Prolyl-4-hydroxylase α(I)39 
which is involved in collagen biosynthesis, and endoglin109 which is a transforming 
growth factor-beta (TGF-beta) co-receptor expressed mainly on endothelial cells and 
involved in cardiovascular development, angiogenesis, and vascular remodeling. The 
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induction of angiogenesis leads to an increase in the vascular density and hence decreases 
the oxygen diffusion distance. However, local blood flow under pathophysiological 
conditions is controlled by modulation of the vascular tone through production of NO via 
activation of inducible nitric oxide synthase (iNOS, NOS II)110, 111, CO via activation of 
heme oxygenase-1112, endothelin-1113, adrenomedullin114, 115, synthesis of catecolamines 
via activation of tyrosine hydroxylase gene116, activation of the α1B-adrenergic receptor 
gene117, all of which involve HIF-1 target genes. 
Transgenic mice expressing HIF-1α under the control of a keratinocyte-specific promoter 
develop hypervascularity but in contrast to VEGF transgenic mice, no vessel leakage or 
inflammation was observed118. This indicates that HIF-1 mediates angiogenesis by 
mechanisms far more complex than simple VEGF induction, probably by recruiting 
additional target genes involved in vessel maturation. 
1.1.4.3. HIF-1 target genes involved in glucose metabolism 
Under conditions of limited oxygen supply, anaerobic glycolysis becomes the 
predominant form of cellular ATP generation (Pasteur effect). Many genes involved in 
glucose uptake and glycolysis such as glucose transporter 1 and 3, aldolase A and C, 
enolase 1, glyceraldehyde phosphate dehydrogenase, hexokinase 1 and 2, lactate 
dehydrogenase A, phosphofructokinase L, phosphoglycerate kinase 1, and pyruvate 
kinase M were identified as HIF-1 target genes119, 120, 121.  
Enhanced lactate production and hence a decrease in pH results from the increase in 
anaerobic glycolysis, potentially limiting this source of ATP despite sufficient glucose 
supply. Transmembrane carbonic anhydrases were reported to be HIF-1 target genes122. 
Carbonic anhydrases regulate the pH by converting protons and bicarbonate to carbon 
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dioxide, which can be taken up by erythrocytes for transportation to the lung. HIF-1 also 
influences mitochondrial function, suppressing both the TCA cycle and respiration by 
inducing pyruvate dehydrogenase kinase 1 and 3 (PDK1 and PKD3) which inactivates 
pyruvate dehydrogenase. PDK1 regulation in hypoxic cells increases intracellular oxygen 
tension, attenuates mitochondrial hypoxic ROS generation, and promotes cell survival 
under anaerobic conditions123, 124, 125.  In addition, HIF-1 also upregulates adenyl kinase 
gene expression. Adenyl kinase catalyze phosphotransfer reactions that are essential in 
the maintenance of cellular energetic economy126.  
Activation of anaerobic metabolism in tumor cells (Warburg effect) explains the 
autonomous response of the cell to hypoxia127, 128. Thus HIF-1 function in hypoxic tumor 
adaptation involves not only increased O2 delivery, but also economizes cellular O2 
consumption. 
1.1.4.4. HIF-1 target genes involved in cell proliferation and viability 
HIF plays a complex role in mediating hypoxia-induced cell proliferation, arrest, and 
apoptosis. HIF-1 has also been shown to be either anti-apoptotic or pro-apoptotic, 
according to the cell type and experimental conditions129. 
Some genes involved in cell cycle control, such as p53130, p21121, serine/threonine kinase-
15 (STK15)131, and carbamoyl phosphate synthetase-aspartate carbamoyltransferase-
dihydroorotase (CAD)132 are HIF-dependent. The antiapoptotic Bcl-2 is down-regulated 
by hypoxia121 whereas the pro-apoptotic family member Nip3133 and its close relative 
Nix134 are up regulated. However, chronic or persistent hypoxia reduces proliferation and 
increases apoptosis in a HIF-1 dependent manner. 
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HIF-1α induces the expression DEC1/Stra13/SHARP-2 and DEC2/SHARP-1135. DEC1 is 
involved in the control of the differentiation and proliferation of chondrocytes115, nerve 
cells116, 117, adipocytes118, and together with the HIF-1 dependent protein Foxp3136 in the 
development of T cells136, 137. On the other hand, DEC2/SHARP-1 worked as a 
transcriptional repressor in vitro136. In addition HIF-1 mediates the biological effects of 
O2 on human trophoblast differentiation and proliferation through TGFß3138 and it 
regulates fetal growth by regulating IGF-II and its bioavalability82, 139. 
1.1.5. Role of HIF-1 in Development 
HIF-1 plays essential roles in embryonic development. Mice with defective genes 
encoding either HIF-1α119, 120 or HIF-1β140 die at midgestation with vascular defects in 
the embryonic and extraembryonic circulation, respectively. However, a growing number 
of evidences suggest multiple roles for HIF-1 in cell differentiation, migration, and 
adhesion during the peri-implantation period141, 142. 
1.1.6. Role of HIF-1 in Tissue ischemia 
HIF-1 plays a pivotal role in the response of tissue to post ischemic injury in vital organs 
such as the heart or brain143. HIF-1α and VEGF expression increases immediately in the 
myocardium after acute myocardial ischemia or early infarction144. HIF-1 activation 
attenuates the expression and secretion of the proinflammatory chemokine IL-8 by 
microvascular endothelium145. HIF-1α  expression results in well-ordered angiogenesis, 
whereas unaccompanied over-expression of VEGF in transgenic mice leads to the 
formation of leaky vessels and inflammation118,146. 
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1.1.7. Role of HIF-1 in Inflammatory Responses 
HIF-1 has been shown to play a role in the regulation of survival and function in the 
inflammatory microenvironment. Overexpression of HIF-1 in vivo enhances localized 
inflammation, while loss of the HIF-1 gene decreases the ability of myeloid cells to 
aggregate, migrate, and blunts their bactericidal activities. The dependence of myeloid 
cells on HIF-1 may be related to their reliance on anaerobic respiration as a means of 
energy production147. In addition, HIF-1α expression plays a role in the differentiation of 
myeloid cells into monocytes and macrophages and is essential for the functional 
maturation of macrophages148. 
1.1.8. Role of HIF-1 In Tumor Progression 
Hypoxic areas are common in malignant tumors and their metastases and tissue hypoxia 
due to inadequate blood supply occurs early during tumor development149, 150, 151. HIF-1α 
is overexpressed in most of common human cancers, including breast, colon, lung, and 
prostate carcinoma152. The overexpression of HIF-1α in tumors is in part due to 
physiological signal (hypoxia and/or glucose deprivation) 1, 153, 154 and in part due to 
genetic mutations that inactivate tumor suppressor genes or activate oncogenes and 
upregulate HIF-1 activity, either through an increase in HIF-1α protein expression, HIF-1 
transcriptional activity, or both155, 83, 156, 157, 158, 159. 
HIF-1 maintains the survival and proliferation of malignant cells in the hypoxic 
conditions of the tumor micro-environment. It decreases oxygen consumption in these 
cells by inhibiting c-Myc, a transcription factor that regulates mitochondrial mass and 
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oxygen consumption and is known to be down-regulated in a variety of human cancers. 
HIF-1 decreases levels of c-Myc by increasing the transcription of MXI1, a repressor of 
c-Myc, and by increasing the rates of proteosome degradation of the c-Myc protein. The 
decreased level of c-Myc in addition to the induction of the glycolytic enzymes lowers 
oxygen consumption in these cells160. HIF-1 also improves O2 delivery to the tumor via 
activation of a number of genes involved in angiogenesis43, 121, 161 
A best evidence for the role of HIF-1 in tumor pathogenesis is the VHL disease in which 
the loss of VHL function leads to HIF-1α overexpression29, 162, resulting in tumors that 
are among the most highly vascularized and invasive human cancers 1, 152, including renal 
cell carcinoma, hemangioblastoma of the central nervous system, retinal angioma, and 
pheochromocytoma163, 164, 165, 166. 
The relationship between HIF-1α and the tumor suppressor p53 is of particular 
significance. Tumor cells subjected to hypoxia undergo p53-mediated apoptosis, which 
represents a powerful selection for cells that have sustained mutations that result in p53 
loss of function167. In normoxic cells, p53 is bound by Mdm2, which targets p53 for 
ubiquitination and proteasomal degradation168, 169. In response to hypoxia, HIF-1 protects 
p53 from degradation170 and upregulates its expression130. On the other hand, p53 
promotes Mdm2-mediated ubiquitination and proteasomal degradation of HIF-1α43. 
Thus, two major consequences of p53 loss-of-function are the prevention of hypoxia-
induced apoptosis and increased expression of HIF-1α43. 
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Table 1: HIF-1 target genes 
5-aminolevulinate synthase104. IGF binding protein 282 
Adenylate kinase 3126. IGF binding protein 382. 
α1B-Adrenergic receptor117.  Lactate dehydrogenase A119, 120. 
Adrenomedullin115, 114  Nip3133 
Aldolase A119, 120. NIX134 
Aldolase C119. Nitric oxide synthase 2 (NOS2)110, 111
Ceruloplasmin103. p21121 
DEC1 (STRA13)135. p35111
DEC2135 Phosphofructokinase L119. 
Endothelin-1 (ET-1)113. Phosphoglycerate kinase 1171. 
Enolase 1119. Plasminogen activator inhibitor 1108. 
Erythropoietin (EPO)5. Prolyl-4-hydroxylase α(I)39. 
Glucose transporter 1119, 120. Pyruvate kinase M119. 
Glucose transporter 3119. Transferrin100. 
Glyceraldehyde phosphate dehydrogenase119. Transferrin receptor101, 102. 
Heme oxygenase-1112 Transforming growth factor β3138 
Hexokinase 1119. Tyrosine hydroxylase116. 
Hexokinase 2119. Vascular endothelial growth factor (VEGF)119, 
120, 121. 
Insulin-like growth factor II (IGF-II)82 VEGF receptor Flt-1107. 
IGF binding protein 1139 HSP70-2172. 
CSB protein173. NDRG1174. and NDRG2175. 
TWIST176. JMJD1A177, 178 . 
serine/threonine kinase-15 (STK15)131. metallothionein-3 (MT-3)179. 
Leptin180. HMG-CoA reductase181. 
CXCR4142. Endoglin109 
miR-210182, 183. Stem cell factor (SCF)184. 
 
14 
1.2. Angiogenesis: Role of Vascular Endothelial Growth Factor (VEGF) 
Formation of blood vessels is an important mechanism for supplying oxygen and 
nutrients to cells that are distant from existing blood vessels150. It occurs via either of two 
mechanisms: vasculogenesis, the de novo organization of endothelial cells into vessels in 
the absence of pre-existing vascular system, which occurs only in the early embryo; and 
angiogenesis, the formation of blood vessels from pre-existing vascular bed185. 
Angiogenesis is involved in vascularization of organs during embryonic development186. 
In the adult, the proliferation rate of endothelial cells is very low compared with the other 
cell types in the body. Physiological exceptions in which angiogenesis occurs under tight 
regulations are found in the female reproductive system and during wound healing. 
Uncontrolled endothelial cells proliferation has pathological implications and plays a 
pivotal role in tumor progression and in inflammatory diseases187. 
Angiogenesis is a complex process that is mediated by the endothelial cells188. Unlike 
quiescent endothelial cell that rarely divide, angiogenic endothelial cells undegro a 
complex sequence of events that includes the secretion of metalloproteases189, 190, 191, 192, 
193, 194 and other matrix degrading enzymes195, 196, cell migration into the newly created 
space197, 198, 199, cell division and proliferation200, 201, and vessel formation202, 203, 204, 205. 
Agiogenesis is a well-regulated process involving a number of stimulators and inhibitors. 
Molecular mediators of angiogenesis include growth factors206, 207, 208 and their receptors, 
matrix receptors, junctional molecules, proteases and others208. 
There are two major differences between physiologic and pathologic angiogenesis. In 
pathologic angiogenesis there is a shift in the balance of positive and negative 
angiogenesis regulators towards the positive molecules209. The second major difference 
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between normal and pathologic angiogenesis is that the vessels formed in diseased tissues 
are highly disorganized210, 211, 212. 
Clinical interest in the control of angiogenesis arises from two distinct viewpoints. In one 
case, the goal is to block the growth of new vessels as a mean to suppress and/or regress 
tumor growth213, 214, or to suppress vessel proliferation in pathologies such as diabetic 
retinopathy215, 216. In the second case, the objective is to induce or stimulate vessel growth 
in patients with conditions characterized by insufficient blood flow, such as ischemic 
heart disease217, 218, 219 and peripheral vascular diseases220, 221, 222, 223, 224, 225. 
1.2.1. Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF), also known as VEGF-A, is a major regulator 
of physiological and pathological angiogenesis226, 227, 228. It is essential for embryonic 
development of vascular system and it was found that the loss of even a single VEGF 
allele results in embryonic lethality due to failure of development and differentiation of 
the vascular system. 229, 230 VEGF also plays a pivotal role in angiogenesis involved in 
wound healing231; and in pathologies such as tumor232, intraocular neovascular 
syndromes233, rheumatoid arthritis234, psoriatic skin235, 236, endometriosis237, 238, and 
Graves’ disease239, 240, 241. Furthermore, VEGF-induced angiogenesis has been shown to 
result in a therapeutic effect in coronary242, 243 and peripheral vascular242, 244, 245 ischemia 
in experimental animals. 
Vascular endothelial growth factor (VEGF/VEGF-A) belongs to the platelet-derived 
growth factor (PDGF)/VEGF supergene family246, 228, which contains at least other six 
homologues, VEGF-B247, VEGF-C247, VEGF-D248, 249, placental growth factor (PlGF) 208, 
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250, VEGF-E251, and snake venom-derived VEGF (svVEGF or VEGF-F)252. With the 
exception of VEGF-E and svVEGF, all members of the family are encoded in the 
mammalian genome. The human VEGF gene has been assigned to chromosome 
6p21.3253. It is organized in eight exons seperated by seven introns. By alternative exon 
splicing, VEGF gene produces five different VEGF isoforms, having 121, 145, 165, 189 
and 206 amino acids (VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206, 
respectively)254, 255, 256. The domain encoded by exons 1–5 contains information required 
for the recognition of the known VEGF receptors Flt-1 and KDR/Flk-1 and is present in 
all VEGF isoforms. The amino acids encoded by exon 8 are also present in all the VEGF 
splice variants. The VEGF isoforms differ in the presence or the absence of the peptides 
encoded by exons 6 and 7 of the VEGF gene257. VEGF165 is the most predominant 
isoform in terms of amount and biological activity226, 258. It is produced by a variety of 
normal and transformed cells. VEGF121 and VEGF189 are also detected in the majority of 
cells expressing VEGF gene259. In contrast, VEGF206 is predominately cell-associated and 
is very rarely secreted254. VEGF isoforms differ in their isoelecteric point and their 
affinity to bind heparin. These differences vastly affect their bioavailability. VEGF121 is a 
freely soluble protein; VEGF165 is also soluable although a significant fraction remains 
bound to the cell surface and the extracellular matrix. In contrast, VEGF189 and VEGF206 
are almost completely sequestered in the extracellular matrix.260. However, these long 
isoforms may be released in a soluble form by plasmin after cleavage at the COOH 
terminus. This action generates a bioactive product comprised of the first 110 NH2-
terminal amino acids of VEGF. These findings suggest that the VEGF proteins may 
become available to endothelial cells by at least two different mechanisms: as freely 
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diffusible proteins, VEGF121 and VEGF165, or after protease activation and cleavage of 
the longer isoforms261. However, loss of heparin binding, whether it is due to alternative 
splicing of RNA or plasmin cleavage, results in a substantial loss of mitogenic activity 
for vascular endothelial cells262. Thus, VEGF has the potential to express structural and 
functional varieties to relent a graded and controlled biological response180. 
VEGF is a potent mitogen for micro- and macrovascular endothelial cells derived from 
arteries, veins, and lymphatics263. VEGF has also reported mitogenic effects on a few 
non-endothelial cell types in culture, including retinal pigment epithelial cells264, 
pancreatic duct cells265, Schwann cells266, and distal airway epithelial cells of the 
developing human lung267. VEGF also seems to act as a survival and antiapoptotic factor 
for newly formed capillaries268. VEGF induces expression of the serine proteases 
urokinase- type and tissue-type plasminogen activators (PA) and also PA inhibitor 1 
(PAI-1) in cultured bovine microvascular endothelial cells269. Plasminogen activators  
permits endothelial cell invasion of the vessel basal lamina, generates products that are 
chemotactic for endothelial cells, activates growth factors localized in the extracellular 
matrix, and modulates some endothelial cell functions, including proliferation and 
migration, with a mechanism independent of their proteolytic activity270, 271, 272, 273. PAI-1 
acts as a positive switch for angiogenesis by promoting endothelial cell migration274. 
Moreover, VEGF increases expression of the metalloprotease interstitial collagenase in 
human umbilical vein endothelial cells. The coinduction of PA and collagenase by VEGF 
is consistent with a prodegradative environment that facilitates migration and sprouting 
of endothelial cells275. VEGF is also known as vascular permeability factor (VPF) based 
on its ability to induce vascular leakage promotion of extravasation of plasma proteins276. 
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Studies have suggested that VEGF may be a factor that induces fenestrations in the 
endothelium of small venules and capillaries, even in regions where endothelial cells are 
not normally fenestrated, and was associated with increased vascular permeability277. The 
increase in microvascular permeability is a major function of VEGF and is an important 
step in angiogenesis associated with tumors and wounds. The consequential plasma 
protein leakage is responsible for the formation of an extravascular fibrin gel that act as a 
substrate for endothelial and tumor cell growth278. VEGF also enhances the translocation 
of cytosolic GLUT1 to the plasma membrane of the endothelial cells and increases their 
permeability to glucose; an action that provides energy during endothelial cell 
proliferation279,280. VEGF promotes expression of vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in endothelial cells. This 
induction results in the adhesion of activated natural killer (NK) cells to endothelial cells, 
mediated by specific interaction of endothelial VCAM-1 and ICAM-1 with CD18 and 
VLA-4 on the surface of NK cells281 and explains the previously observed preferential 
adhesion of IL-2-activated NK cells to the tumor vasculature282. Furthermore, VEGF 
have an inhibitory effect on the maturation of host professional antigen-presenting cells 
such as dendritic cells, without having a significant effect on the function of mature cells. 
Thus VEGF may play an important role on tumor cell immune evasion283. VEGF 
increases angiotensin converting enzyme (ACE) at mRNA and protein levels in cultured 
human endothelial cells284 and concurrently angiotensin-II  also induces the expression of 
VEGF285. The interaction of VEGF and renin-angiotensin system is involved in tumor 
angiogenesis286 and in diabetic retinopathy287. VEGF is also capable of inducing 
vasodilatation and hypotension in vivo288, 289. 
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VEGF exhibits high affinity binding to three distinct membrane tyrosine kinases 
receptors, VEGFR-1 or the fms-like tyrosine kinase (Flt-1)290 , VEGFR-2 or the kinase 
insert domain containing receptor/ fetal liver kinase-1 (KDR/Flk-1)291, and VEGFR-3. It 
also binds co-receptors, such as neuropilin-1 (NRP-1), neuropilin-2 (NRP-2)292 and 
heparan sulfate proteoglycans (HSPGs)293. VEGFRs are related to the platelet-derived 
growth factor (PDGF) family of receptor tyrosine kinases(RTKs)294. They possess an 
extracellular portion consisting of 7 immunoglobulin-like domains, a single 
transmembrane spanning region and an intracellular portion containing a split tyrosine-
kinase domain295. Although both VEGF receptor types are expressed in adult endothelial 
cells, including human umbilical vein endothelial cells, VEGFR-2 appears to mediate 
almost all of the known cellular responses to VEGF including the mitogenic, 
chemotactic, and the antiapoptotic effects of VEGF257, 296, 297. The function of VEGFR-1 
is less well defined, it may be involved in the modulation of VEGFR-2 signaling via 
acting as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding298. A 
number of cell signaling proteins that mediate diverse biological functions of VEGF have 
been identified, including NCK, phospholipase C, mitogen activated protein kinase 
(MAPK), PI3- kinase, focal adhesion kinase (FAK), and paxillin297, 299. 
Vascular endothelial growth factor is expressed in the majority of adult and fetal tissues 
as well as various cultured cell types254. Expression of VEGF mRNA is rapidly and 
reversibly induced by hypoxia both in vitro and in vivo300, 301. VEGF expression can be 
modulated by a variety of cytokines, growth factors, and steroid hormones, including: 
epidermal growth factor (EGF)302, keratinocyte growth factor303, fibroblast growth factor-
4304, Insulin-like growth factor-1305, interleukin-1β306, interleukin-1α307, tumer necrosis 
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factor alpha (TNF-α)308, prostaglandin E307, estradiol309, Progesterone310, 
Corticotropin311, gonadotropins312, and relaxin313, 314. However, from a physiological 
point of view, regulation of VEGF by hypoxia is the most significant and hypoxia-
induced VEGF is the key mediator of compensatory neovascularization in response to 
diminished tissue oxygenation206, 315. VEGF is regulated by hypoxia at both the 
transcriptional and posttranscriptional levels. Transcriptional regulation of VEGF by 
hypoxia is mediated through HIF-dependent and HIF-independent pathways316. HIF-1 
activates VEGF transcription through binding to specific promoter sequences106. Hypoxia 
also leads to stabilization of VEGF mRNA by an HIF-1 independent mechanism317. 
1.3. Mycetoma 
Mycetoma is a chronic subcutaneous granulomatous lesion caused by either true fungi 
(eumycetoma) or by higher bacteria, mainly actinomycetes (actinomycetoma)318. 
1.3.1. Epidemiology and Etiology 
Mycetoma constitutes a major health problem primarily in tropical and subtropical 
regions319, 320. It is endemic in the mycetoma belt around the tropic of Cancer which 
includes Sudan321, Somalia320, Senegal322, Niger323, Mauritania324, Chad325, India326, 
Mexico327, and central and South America328, 329, 330, 331. Areas where mycetoma is 
endemic have a short rainy season 4-6 months with a relative humidity 60–80 % and a 
fairly constant temperature of 30-37° C day and night followed by a dry season of 6–8 
months with a relative humidity 12–30%, day temperature of 45-60° C and night 
temperature of 15-18° C318, 332. The disease has also been repoted in United States333, 334, 
335, United Kingdom336 and in Germany337. 
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Mycetoma can be caused by true fungi (eumycetoma) or by actinomycetes which are 
higher filamentous bacteria (actinomycetoma) and some workers include a third group 
caused by bacteria (botryomycosis). A number of organisms can cause mycetoma and 
about eighteen species of eumycetes and actinomycetes have been isolated from cases all 
over the world338. 
1.3.2. Pathology 
Mycetoma is characterized by the formation of aggregates of the organisms (grains) in 
the tissue, which are visible to the naked eye. The grains vary in color, size, and 
consistency depending on the mycetoma causative agent339. 
Histologic examination of the surgical specimen using haematoxylin and eosin or 
periodic acid-Schiff stains can identify the causal organism and demonstrate the local 
tissue reaction340. Direct microscopy is done by examining crushed grains in 10% KOH. 
Actinomycotic grains show filaments of 0.5 –1 μm whereas eumycotic grains show broad 
mycelia of approximately 15 μm width. The crushed grains could be stained by Giemsa 
for actinomycetes or by Ziel-Neelsen for Nocardi341, 342. 
The mycetoma lesion proved to be well vascularized with abundant capillaries within the 
lesion. The lesion is well oxygenated as evident by the absence of ischemic changes or 
necrosis in the lesion. Mycetoma lesion showed a pathological circulation similar to that 
seen in malignant tumor. This pathological circulation which is more evident in 
eumycetoma is characterized by being brisk and excessive339,343. 
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1.4. Fungal Products and Angiogenesis 
Epolones have firstly been identified as a family of fungal products capable of inducing 
erythropoietin expression under normoxic conditions344, 345. Later, epolones were found 
to efficiently induce HIF-1α protein expression under normoxic conditions and they also 
activate DNA binding of HIF-1346. Several compounds (the 3 sesquiterpene tropolones: 
pycnidione, epoloneA and epolone B, and 8-methyl-pyridoxatin) were isolated, which 
induced reporter gene expression as well as erythropoietin and VEGF production in 
human HepB3 hepatoma cells344, 345. In addition, it was found that the related 
commercially available pyridone, ciclopirox olamine (CPX) acts as a bidentate iron 
chelator capable of inducing HIF-1α stability, VEGF expression, and angiogenesis347. 
1.5. Objectives of the Study 
The objectives of this study are to: 
1. assess the vascularity of eumycetoma lesion produced by Madurella 
mycetomatis. 
2. determine the concentration of HIF-1 in eumycetoma lesion produced 
by Madurella mycetomatis. 
3. determine the concentration of VEGF and ADM mRNA in 
eumycetoma lesion produced by Madurella mycetomatis. 
4. investigate the effect of Madurella mycetomatis products on the 
activation of HIF-1 and the expression of its down stream genes mRNA. 
 
23 
Chapter Two 
Materials 
and 
Methods 
2:. MATERIALS AND METHODS 
2.1. Description of the Study 
This study consists of an in vivo experiments and in vitro expirements. For the in vivo 
cross sectional study we collect tissue specimens from 23 patients with mycetoma lesion 
to investigate the vascularity of the lesion and the expression of HIF-1 and its 
downstream genes products. In the in vitro experiments we use the HepG2 cells culture to 
study the effects of Madurella mycetomatis products on the expression of HIF-1 and its 
downstream genes products. The proposal for this study was approved by the research 
committee of the faculty of medicine- university of Khartoum in December 2003. 
2.2. Collection of Human Tissue: 
Human tissue samples were collected from 23 patients who were already diagnosed with 
black madura and underwent surgical excision for curative purpose at Mycetoma 
Research Center - Soba Teaching Hospital. Two tissue specimens were taken from each 
patient: one grain rich specimen was taken from the center of the lesion and another grain 
free specimen was taken from the periphery of the lesion. Each of the two specimens was 
divided into two parts: one part was snap frozen in liquid nitrogen and the other part was 
kept in 10% formalin. 
2.3. Preparation of the Fungal Culture Supernatant 
2.3.1. Culture Media 
Madurella mycetomatis strain 14 and strain 55 were grown in both RPMI (colourless 
RPMI medium from BioWitthaker; supplemented with 6 ml 0.165M MOPS/500 ml 
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RPMI.; Supplemented with L-glutamine) and minimal media (15 mM glucosis, 10 mM 
MgSO4, 29.4 mM KH2PO4, 13 mM glycine, 3 uM thiamine) 
2.3.2. Culture protocol:  
10 ml of culture media were inoculated with Madurella  mycetomatis strain 14 or strain 55. The 
culture was incubated for 5 days at 37oC and then sonicated for 20 seconds at 28 micron 
(Soniprep, Beun de Ronde, The Netherlands). The sonicated suspension was added to 40 ml 
RPMI or minimal medium and incubated for 10 days at 37oC. After centrifugation for 5 min at 
2158 g (Hettich –Rotana AP), The supernatant was removed and 10-15 ml NaCl were added to 
wash the sample and the culture was centrifuged for 5 min at 2158 g. The supernatant was 
removed and the mycelia were resuspended in 15 ml RPMI or minimal medium. The suspension 
was sonicated again for 20 seconds at 28 micron. The transmission of the suspension was 
measured at a wavelength of 660 nm and then the suspension was adjusted to a transmission of 
70%. 10 ml of this supsension were cultured in RPMI or minimal medium for 2 or 4 weeks and 
then centrifuged for 5 min at 2158 g to obtain the culture supernatants, which was then stored this 
at –80oC for later use. 
2.4. HepG2 Cell Culture and Subculture: 
HepG2 cells (American Type Culture Collection, HB8064, Rockville, MD, USA) were grown in 
a 75 cm2 plates (Sellstar, Germany) and were maintained in RPMI 1640 (BioWhittaker, 
Cambrex, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS, Sigma, Munich, 
Germany) and 100 units/ml penicillin, and 100 units/ml streptomycin in a humidified 
atmosphere at 20.9% O2, 5% CO2, and 74.1% N2. The medium was regularly changed every 
other day. 
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Cultures were viewed regularly using an inverted microscope to assess the degree of 
confluency and to confirm the absence of bacterial and fungal contaminants. 
Cells were split whenever their confluency is around 80%. For the splitting and 
subculturing the cells, spent medium was sucked from the culture plate using a Pasteur 
pippet. The cells were washed twice with PBS using a volume equivalent to half the 
volume of culture medium. To detach the cells, the plates were incubated for 2-10 
minutes at 37° C with 2 mL of trypsin (0.25%). The cells were then examined using an 
inverted microscope to ensure that all the cells are detached and floating. The side of the 
plate was gently tapped to release any remaining attached cells. To inactivate the trypsin, 
8 mL of pre-warmed serum-containing medium were added to the plate. For the 
subculture of the HepG2 cells, 13 mL of pre-warmed medium were pipetted into new-
labelled plates and then 2 ml of the cells suspension were added to each plate. 
For the experiments, cells were cultured to 70-80% confluence in 35 mm Petri dishes 
containing 1 mL of medium. The cells were incubated for 4 or 6 hours with the test 
medium. A subset of cell was cultured in a blank medium and another subset was 
exposed to 100 µmol/L cobalt chloride (CoCl2; Sigma), these two subsets were used as 
negative and positive control, respectively. Cellular responses to CoCl2 have been shown 
to mimic that for hypoxia in signal transduction and transcriptional regulation348, 349. To 
achieve hypoxic conditions, culture dishes were placed in a Heraeus incubator (Hanau, 
Germany) with 3% O2, 92% N2, 5% CO2. 
For the mRNA quantification and ELISA detection of VEGF, cells were incubated with 
the test media for 6 hours. At the end of the incubation the cell culture supernatants were 
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pipetted into 1.5 ependorf tubes and stored at –80° C until submitted for ELISA detection 
of VEGF. 700 μL GTC solution were added to each 35 mm well. The cell lysates were 
stored at –20 C until submitted for quantitative PCR. 
For Western blot detection of HIF-1α, cells were incubated with the test media for 4 
hours. After the treatment cells were washed with ice cold PBS and then lysed in 55 μl 
extraction buffer (300 mM sodium chloride, 10 mM Tris (pH 7.9), 1 mM EDTA, 0.1% 
Nonidet P-40, 1x protease inhibitor mixture) (Roche Applied Science, Basel, 
Switzerland) for 20 min on ice and centrifuged (3600 x g at 4 °C for 5 min). Protein 
concentration was determined using the Bio-RAD Laboratories protein assay reagent and 
stored at –80 °C. 
For the assessment of VEGF secretion by HepG2 cells, HepG2 cells were incubated with 
the test media for 6 hours. The supernatants were pipetted into 1.5 Eppendorf test tubes 
and were stored at – 80° C. 
2.5. Tissue Paraffinization 
Fresh tissue was cut into appropriate size specimens and placed into 10% Neutral 
Buffered Formalin. The specimens were incubated at room temperature for 8 to 12 hours. 
From the 10% Neutral Buffered Formalin, the fixed specimens were placed into 50% 
Ethanol for 45 minutes, 70% Ethanol for 45 minutes, 95% Ethanol for 45 minutes, and 
then in 100% Ethanol for 45 minutes twice. The specimens were transferred to Xylene 
and were incubated for 45 minutes and then transferred to fresh Xylene and were 
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incubated for another 45 minutes. Then the specimens were added to molten paraffin and 
were infiltrated for 6 hr or overnight. The paraffin was changed every 12 hours, for at 
least three changes before embedding. The infiltrated specimens were then placed into a 
block of molten paraffin and were allowed to cool and solidify. 
2.6. Preparation of the Cell Lysates and Human Tissue Homogenization: 
2.6.1. Preparation of diethyl pyrocarbonate (DEPC) treated water 
DEPC was added to distill deionized water to a final concentration of 0.1% (v/v). After 
thorough shaking, the mixure was incubated at 37° C for 12 hours, and then autoclaved at 
121° C for 20 minutes. 
2.6.2. Preparation of Guanidinium Isothicyanate 4M 
For the preparation of 500mL, 250 mL of DEPC treated water was added to a flask. 
While the flask was on a magnetic stirrer, 236.4 gm GTC was added slowly within one 
hour. Then 4.18 mL 3M NaOAc (pH 5.2) was added. The flask was filled up to 500ml 
with DEPC treated water and then 3.75 mL β Mercaptoethanol was added 
2.6.3. Tissue Homogenization 
Liquid nitrogen frozen tissue was homogenized in guanidinium isothiocyanate 4M 
solution, in a ratio of 10 mL to 1 gram of tissue, using a Polytron homogenizer (Diax, 
Germany). Tissue homogenates were kept at –20º C and were transported to Germany in 
dry ice. 
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2.7. Isolation of total RNA: 
Total RNA was isolated from human tissue homogenates and from cell culture by the 
acidic guanidinium thiocyanate-phenol-chloroform extraction method350. 
70 μL 2M Sodium Acetate (pH 4.0), 700 μL of the homogenate, 550 μL phenol (pH 4.5) 
and 350 μL phenol:chloroform:isoemyl were added to labeled 2 mL Eppendorf tubes. 
The tubes were vortexed for 10 seconds and then incubated in ice for 15 – 60 minutes. 
After incubation, the tubes were vortexed for 10 seconds, and then centrifuged for 30 
min, 4° C, 13000 rpm. 600 μL isopropanol was added to the new-labeled 1.5 mL 
Eppendorf tubes. The upper aqueous phase was transferred from the centrifuged tubes to 
the new tubes. The tubes were then incubated at –20° C for at least 12 hours. After 
incubation the tubes were centrifuged for 30 min, 4° C, 13000 rpm. After centrifugation 
RNA pericipitated as a pellet at the tips of the tubes. The aqueous phase was removed 
carefully and the tubes were left inverted for 30 minutes to dry. 300μL GTC and 500 μL 
isopropanol were added to the RNA pellet. The tubes were vortexed for 10 seconds and 
then incubated at –20° for at least 1 hour. The tubes were centrifuged for 30 min, 4° C, 
13000 rpm. After centrifugation RNA pericipitated again as a pellet at the tips of the 
tubes. The aqueous phase was removed carefully and the tubes were left inverted for 30 
minutes to dry. 500 μL ethanol 75% were added to the RNA pellet. The tubes were 
vortexed for 10 seconds and then incubated for 15 min at room temperature abd then 
centrifuged for 15 min, 4° C, 13000 rpm. The aqueous phase was removed and 20μL - 
30μL DEPC treated water was added according to the size of the RNA pellet. The tubes 
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were shortly spined and then incubated in a rotating water bath at 56 – 60° C for 10 
minutes. RNA was stored at –20°  C. 
2.8. Measurement of Total RNA Concentration: 
1 μL of RNA solution was added to 99 μL of distilled deionised water in a 1.5 mL 
Eppendorf tube. Total RNA concentration was determined using a spectrophotometer 
(Bio-Rad) with a conversion factor 40 at 260nm, where 1 absorbance unit (A260) = 40µg 
of single-stranded RNA/ml. The purity was estimated by the relative absorbances at 260 
and 280nm and RNA purity was accepted for a A260/A280 ratio between 1.6 to 2. 
2.9. First Strand cDNA Synthesis 
cDNA was synthesized using 1 μg RNA from cell lysates or 2 μg RNA from human 
tissue homogenates as template. Oligo(dT) was used as a primer at a concentration of 0.5 
μg for each 1 μg of total RNA. A mixure of RNA and Oligo(dT) was prepared in a 
neuclease free 500 μL Eppendorf tube and  DEPC treated water was added to a total 
volume 12 μL. The tubes were heated to 68°C for 10 minutes to melt secondary structure 
within the template and then cooled immediately on ice to prevent secondary structure 
from reforming. 5 μL of M-MLV RT 5X reaction buffer (250mM Tris-HCl (pH 8.3 at 
25°C), 375mM KCl, 15mM MgCl2, 50mM DTT), 5 μL dNTPs (2.5 mM dATP, 2.5 mM 
dCTP, 2.5 mM dGTP, 2.5 mM dTTP), 2.5 μL DEPC treated water, and 0.5 μL  (200 
units/μL) Moloney murine leukemia virus reverse transcriptase  (Promega, Heidelberg, 
Eggenstein, Germany) were added. The reverse transcriptase reaction was carried using 
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the following thermal protocol: 45° C for 90 minutes, 52° C for 30 minutes, 95° C for 15 
minutes. 
cDNA was stored at 4° C and was used for both qualitative and quantitative PCR. 
2.10. Qualitative PCR: 
The qualitative polymerase chain reaction was carried in a 200 μL thin wall PCR 
Eppendorf tube. 1 μL cDNA was used as a template. 5 μL of 10x buffer (100 mmol/L 
Tris-HCl , 500 mmol/L KCl, 1% Triton® X-100), 4 μL dNTPs (2.5 mM dATP, 2.5 mM 
dCTP, 2.5 mM dGTP, 2.5 mM dTTP), 1.5 μL 50 mM MgCl2, 1 μL of each 5´- and 3´-
primer (200 pmol/L) 37.5 μL DEPC treated water, and 0.15 μL Taq polymerase 
(Invitrogen) were added to the tube.  The tables below show the primer sequence and the 
thermal protocols used for the amplification of β actin, VEGF, and ADM. 
 β actin VEGF ADM 
Number of 
cycles 
28 35 35 
 Temperature Time 
(minutes) 
Temperature Time 
(minutes) 
Temperature Time 
(minutes) 
Initial 
denaturation 
95° C 3:00 95° C 3:00 95° C 3:00 
Denaturation 95° C 0:30 95° C 0:30 95° C 0:30 
Annealing 57° C 1:00 59° C 1:00 60° C 1:00 
Extension 72° C 1:30 72° C 1:30 72° C 1:30 
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Final 
extension 
72° C 10:00 72° C 10:00 72° C 10:00 
The PCR product was stored at 4° C until subjected to electrophoresis on a 2 % agarose gel. 
2.11. Gel Preparation and Electrophoresis 
2 grams of agarose gel were dissolved in 100 mL by heating for 1 minute in a microwave 
oven. 2 μL ethidium bromide (50 μg/mL) were added and the gel was boiled for 1 
minute. The gel was poured in the gel tray and a comb was mounted. The gel was left for 
1 hour to cool down. 
The PCR products were loaded into the gel. The gel tray was mounted into the 
electrophoresis chamber and 1x Tris-Acetate-EDTA buffer (TAE) (40 mM tris (pH 7.6), 
20 mM acetic acid, and 1 mM EDTA) was added. The gel was electrophoresed at 100 V 
for 2 minutes and then flooded with 1x TAE buffer and electrophoresed at 80 V for 60 
minutes. The gel was visualized under ultra violet light. 
2.12. Quantitative PCR: 
Gene expression of human VEGF and ADM were quantitated using power SYBR Green 
master mix (Applied Biosystem) and the Gene Amp®5700 sequence Detection System 
(PE Biosytems). The PCR reactions were set up in a final volume of 25 µL: 0.5 µL 
cDNA, 1 x Reaction Buffer with SYBR Green, 10 pmol forward (F) and 10 pmol reverse 
primer (R). Primer sets used for VEGF: (F) 5`-CTC CGA ACA ATC ACT GCT-3` and 
(R) 5`-GGT CAT CTG T-CC CCT GTC CT-3`; ADM (F) 5`-GGA TGC CGC CCG CAT 
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CCG AG-3` and (R) 5`-GAC ACC AGA GTC CGA CCC GG-3`; ß-actin (F) 5`-TCA 
CCC ACA CTG TGC CCA TCT ACG A-3` and (R) 5`-CAG CGG AAC CGC TCA 
TTG CCA ATG G-3`; HIF-1α (F) 5`-GCT GGC CCC AGC CGC TGG AG-3` and (R) 
5`-GAG TGC AGG GTC AGC ACT AC-3`. 
Oligonucleotides were purchased from Life Technology (Gibco-BRL). Agarose gel 
electrophoresis confirmed the specificity of the amplification product. Tenfold dilutions 
of purified PCR products (High Pure PCR Product Purification Kit, Roche) starting at 1 
pg to 0.01 fg were used as standards. Amplification conditions were set to 10 min at 95°C 
followed by 40 PCR cycles (15 seconds at 95°C, 1 min at 60°C). The quantity of cDNA 
used in each reaction was normalized to the ß-actin cDNA and was expressed as (cDNA 
sample / cDNA ß-actin) x 1000. 
2.13. Immunohistochemistry 
Immunohistochemistry was performed on depariffinized 6 μm-thick sections. The 
sections were deparaffinized and rehydrated as follows: three times for 5 minutes in 
xylene; two times for 5 minutes in 100% ethanol; two times for 5 minutes in 95% 
ethanol; and once for 5 minutes in 80% ethanol. The sections were then mounted onto 
labeled slides. After been boiled in sodium citrate buffer pH 6.0 for 1:30 hours, the slides 
were placed in oxidation blocking solution (PBS + 3% H2O2) for 10 minutes. Then the 
slides were incubated with the primary antibody (dilution 1:20) overnight at 4° C. For the 
detection of HIF-1 α, a monoclonal mouse anti-human HIF-1α IgG1 antibody (BD 
Bioscience) was used as the primary antibody. For the detection CD31 monoclonal 
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mouse anti-human CD31 IgG1 (Dako, Copenhagen, Denmark) was used as a primary 
antibody. After washing in TBS for three times to remove the excess antibodies, the 
slides were then incubated with the secondary antibody (dilution 1:2000) for 1 hour at 
room temperature. Donkey anti mouse biotin (Dianova JI) was used as the secondary 
antibody. Then the slides were incubated with peroxidase linked streptavidin 
(Streptavidin POX) (Dianova JI), (dilution 1:250) for 45 minutes at room temperature. 
For counterstaining, the slides were incubated in vector nuclear fast red (Vector 
laboratories, USA) for 10 minutes at room temperature. 
Microvessel counts were made on x200 field (x20 objective and x10 ocular, 0.74 
mm2/field). Vessels were counted in 10 20 randomly selected visual fields per section 
using light microscope. The number of HIF-1α positive cells per visual field was counted 
in 20 randomly selected visual fields per section under light microscope using x40 
objective and x10 occular lenses. 
2.14. Western Blot 
After addition of 1/4 volume of sample buffer [50 mmol/L Tris (pH 6.8), 2% SDS, 5% β-
mercaptoethanol, 0.0125% bromophenol blue, 1% glycine], 50 to 75 µg of total cell 
lysate per lane were subjected to 7.5% SDS-PAGE and transferred onto a nitrocellulose 
membrane (0.2 µm pore size, Schleicher and Schuell, Dassel, Germany). The efficiency 
of protein transfer and equal loading was confirmed by staining the nitrocellulose 
membrane with Ponceau S (Sigma, Steinheim, Germany). Membranes were blocked 
overnight at 4°C with 5% nonfat dry milk in TBS-T [10 mmol/L Tris (pH 7.5), 100 
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mmol/L NaCl, 0.05% Tween 20], then washed in TBS-T and incubated with the primary 
antibody at room temperature for 2 hours with gentle shaking. Primary antibodies used 
were mouse monoclonal antibody raised against human HIF-1α (1:250, Transduction 
Laboratories, Heidelberg, Germany) and mouse monoclonal antibody raised against α-
tubulin (1:500, Santa Cruz Biotech, Heidelberg, Germany). After washing with TBS-T, 
the blot was incubated with horseradish peroxidase–conjugated anti-mouse 
immunoglobulin G (IgG) antibody (Sigma). Immunoreactive proteins were visualized 
using a chemiluminescence detection system in which the membrane is incubated in a 
detection solution for 1 min [100 mmol/L Tris-Cl (pH 8.5), 2.65 mmol/L H2O2, 0.45 
mmol/L luminol, 0.625 mmol/L p-coumaric acid] followed by exposure to X-ray films 
(Agfa, Mortsel, Belgium). 
2.15. ELISA Protocol 
2.15.1. Plate Preparation 
0.4 μg/mL capture antibody solution was prepared by diluting the capture antibody 
(polyclonal goat IgG anti Human VEGF antibody: R&D Systems, AF – 293 - NA) in 
PBS. 100 μL/well of the capture antibody solution was transferred to a 96 wells of 
microtiter plate (Maxisorb, Nunc). The plate was sealed and incubated overnight at 4º C. 
The wells were then aspirated and washed with 200 μL/well wash buffer (0.05% Tween 
20 in PBS, pH 7.4) , repeating the process 3 times for a total of 4 washes. After the last 
wash, wash buffer was thoroughly removed. The plate was blocked by adding 300 μL of 
blocking buffer (PBS containing 1% BSA and 0.05% NaN3) to each well. The plate was 
incubated at room temperature for 2 hours after which the wells were aspirated and 
washed as described above 
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2.15.2. Assay Procedure 
Standard dilutions (200, 100, 50, 20,5, and 2.5 pg/mL) ware prepared by diluting the 
standard recombinant human VEGF (R&D Systems, VE – 293) in PBS. 100 μL of 
sample or standard was added to each well. The plate was sealed and incubated at room 
temperature for 2 hours after which the wells were aspirated and washed as described 
above. Then 100 μL (200 ng/mL in TBS pH 7.3) of the biotinylated detection antibody 
(Biotinylated anti-goat antibody, R&D Systems, BAF-293) were added to each well. The 
plate was sealed and incubated at room temperature for 2 hours followed by aspiration 
and washing as described above. 100 μL ExtrAvidin-peroxidase (Sigma, E2886) at a 
dilution 1:20000 in TBS was added to each well. The plate was sealed and incubated at 
room temperature for 40 minutesafter which wells were aspirated and washed as 
described above. 100 μL of substrate solution (3,3´-5´,5- tetramethylbenzidine, TMB) 
(Liquid substrate system, Sigma, T8665) were added to each well. Plate was incubated 
for 30 minutes at room temperature in a dark room. Then 50 μL of stop solution (1.0 M 
H2SO4) were added to each well. The optical density of each well was determined within 
30 minutes, using a microtiter plate reader (Bio-RAD 680) set to 540nm. 
2.16. Cells Transfection and Reporter Gene Assay 
HepG2 cells were transiently transfected with the HIF-dependent firefly luciferase 
reporter gene construct pH3SVL, containing a total of 6 HIF-1 DNA-binding sites 
derived from the transferrin 3´ enhancer controlling the pGL3 vector (Promega, 
Heidelberg, Germany). The reporter plasmid contains the luciferase gene under the 
control of HIF-1 binding sites.  
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Cells were transfected by liposome-mediated techniques. 1 µg of pH3SVL was 
transfected into HepG2 cells, at 50-60 % confluence in 24-well plates, using Tfx-20 
(Promega). The transfection medium was prepared with Tfx-20 reagent/plasmid mixture 
(3:1) and RPMI medium in a total volume of 200 µl. The transfection medium was 
incubated at room temperature for 15 minutes. Cells were incubated with the mixture for 
1 hour at 37° C. After removal of the transfection medium, 500 µl of fresh RPMI medium 
supplemented with 10% fetal calf serum and 100 units/ml penicillin, and 100 units/ml 
streptomycin were added and the cells were incubated for 24 hours. 
Test media were prepared by adding fungal culture supernatant to RPMI medium at a 
ratio 1:3. RPMI with or without CoCl2 were used as negative and positive controls, 
respectively. 
After treatment with test media under normoxic or hypoxic atmosphere for 24 hour, cells 
were lysed in a buffer made of 2 mM dithiothreitol, 2 mM EDTA, 10% glycerin, 1% 
Triton X-100, 25 mM Tris, pH 7.8. Luciferase activity was determined with the luciferase 
assay system (Promega) and normalized to total cellular protein. All transfections were at 
least done in three separate culture dishes; data are expressed as means ± S.D. 
2.17. Statistical Analysis 
The data are presented as means ± standard deviation (SD) unless stated otherwise. 
Paired-samples Student’s t test was used to determine significant differences between two 
group means. Analysis of variance and Tukey’s honestly significant difference post hoc 
tests were used to compare mean ± SD between various groups. P value < 0·05 was 
considered statistically significant. 
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Chapter Three 
Results 
3:. RESULTS 
3.1. The Vascularity of the Mycetoma Lesion 
We first investigated the vascularity of mycetoma lesion caused by Madurella 
mycetomatis in 23 patients. Human tissue specimens were collected from patients who 
were undergoing surgical exision for curative pupose. The specimens were stained 
immunohistochemically, targeting CD31 which is expressed by endothelial cells. 
Specimens taken from a grain rich tissue were compared with a grain free tissue taken 
from the same exised lump. The vessels were counted under the objective 40x in 20 
randomly selected fields. The vessel count was found to be higher in the grain rich tissue 
compared with the grain free tissue (17.8± 8.1, 12.6± 6.29; p = 0.008, n=23). 
3.2. Expression of HIF-1α in Mycetoma Lesion 
3.2.1. Accummulation of HIF-1α in the endothelial cells in the vicinity of the 
mycetoma grains  
We quantified HIF-1α in human tissue specimens by counting HIF1α positive cells in 
immunohistochemically stained specimens. HIF-1α positive cells were counted under 
objective 100x in 50 randomly selected fields. HIF-1α positive cells count in specimens 
taken from a grain rich tissue were compared with a grain free tissue taken from the same 
exised lump. HIF-1α positive cells were found to be more abundant in the grain rich 
tissue compared with the grain free tissue (62.1± 43.74, 30.4± 21.14; p = 0.003, n=23) 
(Figure 3.1.) 
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3.2.2. Expression of HIF-1α mRNA in the mycetoma lesion 
HIF-1α mRNA was quantified after extraction of total RNA from homogenized human 
tissue taken from a grain rich tissue as a study sample and a grain free tissue as a control. 
First strand cDNA was prepared from 2 µg total RNA using an oligo(dT) primer , HIF-1α 
cDNA and β-actin cDNA were subjected to quantitative real-time PCR. HIF-1α cDNA 
was normalized to β-actin cDNA and expressed as relative units × 1000. There was a 
significant difference in the concentration of HIF-1α mRNA in the grain rich tissue and 
the grain free tissue (174.5± 63.02, 111.8± 76.11; p = 0.008, n=23). (Table 3.1.) 
3.2.3. Expression of VEGF mRNA and ADM mRNA in the mycetoma lesion 
Moreover, the expression of the down stream HIF-1 genes were investigated by 
quantifying the mRNA for VEGF and ADM. Total RNA was extracted from 
homogenized human tissue taken from a grain rich tissue as a study sample and a grain 
free tissue as a control. First strand cDNA was prepared from 2 µg total RNA using an 
oligo(dT) primer , and subjected to quantitative real-time PCR for ADM, VEGF, and β-
actin. VEGF and ADM cDNA were normalized to β-actin cDNA and expressed as 
relative units × 1000. VEGF and ADM mRNA were significantly higher in grain rich 
tissue. (VEGF: 7.7± 4.86, 3.0± 3.05; p = 0.001, n=23); (ADM: 9.6± 4.54, 2.3± 2.08; p = 
0.001, n=23). The overexpression of ADM mRNA (4.17 folds) was more pronounced 
compared to that of VEGF mRNA (2.57 folds). There was no correlation between VEGF 
expression and ADM expression or between VEGF, ADM expression and HIF-1 
expression. (Table 3.1.) 
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3.3. Effect of Madurella mycetomatis Culture Supernatant on the Expression 
of HIF-1α 
3.3.1. Madurella mycetomatis culture supernatant accummulates HIF-1α 
We investigated the effect of Madurella mycetomatis culture supernatant on the 
expression of HIF-1α and its target genes in HepG2 cell culture. HepG2 cells were 
incubated for 4 hours under normoxic (21% O2) and hypoxic (3% O2) condition in the 
presence or absence of the supernatant obtained from a culture of Madurella mycetomatis 
strain 55 and strain 14 grown in minimal media for 4 weeks. Whole cell extracts (50 g) 
were used for Western blots for HIF-1α and α-tubulin as a loading control. It was clear 
that HIF-1α concentration was increased in the supernatant treated cells compared with 
the control (Figure 3.2).We also quantify HIF-1α mRNA expression in Madurella 
mycetomatis culture supernatant treated HepG2 cells using quantitative real time PCR 
analysis, no significant change was found in the expression of HIF-1α mRNA under the 
effect of  Madurella mycetomatis culture supernatant. 
Transcriptional activity of the fungal supernatant-induced HIF-1 was determined in 
reporter gene assay using the luciferase gene under the control of six HIF-1-binding sites 
from the transferrin enhancer. After transient transfection, HepG2 cells were incubated 
under normoxic or hypoxic conditions in the presence or absence of supernatants 
obtained from Madurella mycetomatis strain 14 or strain 55 grown in minimal media for 
2 weeks or 4 weeks. Both the 2 weeks and the 4 weeks old culture supernatant obtained 
from strain 14 culture increased the luciferase activity under both normoxic and hypoxic 
conditions The 4 weeks old culture of strain 55 culture increased luciferase activity under 
both normoxic and hypoxic conditions, while the 2 weeks old culture of strain 55 
supernatant increased luciferase activity only under hypoxic conditions. (Figure 3.3. and 
Figure 3.4.) 
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3.3.2. Effect of Madurella mycetomatis Culture Supernatant on the Expression 
of VEGF mRNA and ADM mRNA 
To determine whether HIF-1 activation by fungal supernatant affects expression of HIF-
1-regulated genes, changes in mRNA levels for VEGF and ADM that are reported to be 
regulated by HIF-1105, 106, 351 were studied. A qualitative PCR was performed first using 
supernatants obtained from Madurella mycetomatis strain 55 culture (Figure 3.3). Using 
quantitative real time PCR analysis, we found that Madurella mycetomatis strain 14 
culture supernatant had significantly increased the expression of both VEGF mRNA and 
ADM mRNA under both normoxic and hypoxic conditions. The effect of Madurella 
mycetomatis strain 14 culture supernatants on VEGF expression was comparable with the 
effect of 100 μM CoCl2 under both normoxic and hypoxic conditions, irrespective to the 
incubation period of the fungal culture from which the supernatant had been obtained. 
ADM expression was increased to a level comparable with that produced by 100 μM 
CoCl2 under normoxic and hypoxic conditions only when HepG2 cells were treated by 
fungal supernatant obtained from a 4 weeks old culture. Supernatant obtained from the 2 
weeks old fungal culture was able to raise the level of ADM mRNA to a level 
comparable with that produced by 100 μM CoCl2 only under hypoxic conditions but not 
under normoxic condition (Table 3.2 and Table 3.3). The expression of ADM mRNA in 
HepG2 cells treated with supernatants obtained from either 2 weeks or 4 weeks old 
Madurella mycetomatis strain 55 cultures was significantly increased to a level 
comparable with that produced by 100 μM CoCl2 under normoxic condition (Table 3.4.). 
Only the supernatant obtained from a 4 weeks old Madurella mycetomatis strain 55 
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culture was able to increase the expression of VEGF mRNA to a level comparable with 
that produced by 100 μM CoCl2 by HepG2 cells under normoxic condition (Table 3.5.). 
3.4. Secretion of VEGF by HepG2 Cells under the Effect of Fungal 
Supernatants 
To investigate the effect of Madurella mycetomatis culture supernatant on the secretion 
of VEGF by HepG2 cells that is reported to be regulated by HIF-1, we used ELISA to 
analyze the level of VEGF in HepG2 culture supernatant after incubating the cells with 
supernatant from Madurella mycetomatis strain 14 and strain 55 cultures for 6 hours. 
Supernatant from Madurella mycetomatis strain 14 significantly increased the secretion 
of VEGF by HepG2 cells (p value = 0.020) but the increase was not significant when the 
cells had been treated by supernatant from Madurella mycetomatis strain 55 culture 
(Figure 3.8.). 
3.5. Dexamethasone Suppress the Fungal Supernatant-Induced VEGF 
Secretion 
We also investigated the effect of dexamethasone on the fungal supernatant-induced 
VEGF secretion. Dexamethason was found to abolish the effect of fungal supernatant on 
the secretion of VEGF by HepG2 cells. Dexamethasone significantly abolished the effect 
of supernatant from Madurella mycetomatis strain 14 culture on the secretion of VEGF 
by HepG2 cells, (p = .041, n=3). (Figure 3.8.) 
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Figure 3.1: Accummulation of HIF-1α in the mycetoma lesion 
 
Tissue specimens were obtained from the grain-free periphery (A) and from grain-
rich center (B) of eumycetoma lesion. 6 μm sections were stained using monoclonal 
mouse anti-human HIF-1α IgG1 antibody (BD Bioscience) as the primary antibody 
and Donkey anti mouse biotin (Dianova JI) as the secondary antibody. Cell 
immunoreactivity was scored based on nuclear and cytoplasmic staining. 
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Table 3.1.: Expression of HIF-1α, VEGF, and ADM mRNA in the mycetoma lesion 
 
Tissue 
site 
Normalized 
mRNA level 
(mean ± SD) 
Paired difference 
of normalized 
mRNA level 
(mean ± SD) 
p value 
Center 174.46±63.02
HIF-1α 
Periphery 111.81±76.11
62.64±103.89 0.008
Center 7.68±4.86
VEGF 
Periphery 3.01±3.05
4.67±6.03 0.001
Center 9.64±4.54
ADM 
Periphery 2.29±2.08
7.35±4.14 < 0.001
Liquid nitrogen frozen tissue specimens, taken from 23 patients with eumycetoma, 
were homogenized in guanidinium isothiocyanate 4M solution, in a ratio of 10 mL to 
1 gram of tissue, using a Polytron homogenizer. Total RNA was extracted, cDNA 
was prepared from 1 µg total RNA using an oligo(dT) primer , and subjected to real-
time PCR for HIF-1α, VEGF, ADM, and β-actin quantification. HIF-1α, VEGF, and 
ADM cDNA was normalized to β-actin cDNA and expressed as relative units × 1000. 
Levels of HIF-1α, VEGF, and ADM cDNA in the grain rich specimen taken from the 
center of the lesion were compaired to a grain free specimen taken from the lesion 
periphery 
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Figure 3.2: Effect of culture supernatant from Madurella mycetomatis strain 55 
and Strain 14 on HIF-1α protein accumulation. 
HepG2 cells were incubated for 4 hours under normoxic (21% O2) and hyoxic 
(3% O2) conditions in the presence or absence of the supernatant obtained from 
a culture of Madurella mycetomatis strain 55 and strain 14 grown in minimal 
media for 4 weeks. Whole cell extracts (50 g) were used for Western blots for 
HIF-1α and α-tubulin as a loading control. 
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Figure 3.3: Induction of HIF-1 transcriptional activity by Madurella mycetomatis 
strain 14 culture supernatant
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HepG2 cells were transfected with pH3SVL luciferase reporter plasmids containing the 
luciferase gene under control of six HIF-1 binding sites from the transferrin 3 enhancer 
(HRE-luc). Transfected cells were incubated for 24 hour under normoxic (21% O2) or 
hypoxic (3% O2) conditions in the presence of supernatant obtained from a culture of 
Madurella mycetomatis strain 14 (mm14) grown in minimal media for 2 (2W) or 4 weeks 
(4W) or in the presence of 100μM CoCl2 as a positive control.. Luciferase activity was 
determined with the luciferase assay system (Promega). All transfections were at least 
done in three separate culture dishes; Luciferase activities were expressed as fold 
induction compared with untreated control cells, data are expressed as means ± S.D. 
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Figure 3.4: Induction of HIF-1 transcriptional activity by Madurella mycetomatis 
strain 55 culture supernatant
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HepG2 cells were transfected with pH3SVL luciferase reporter plasmids containing the 
luciferase gene under control of six HIF-1 binding sites from the transferrin 3 enhancer 
(HRE-luc). Transfected cells were incubated for 24 hour under normoxic (21% O2) or 
hypoxic (3% O2) conditions in the presence of supernatant obtained from a culture of 
Madurella mycetomatis strain 55 (mm 55) grown in minimal media for 2 (2W) or 4 
weeks (4W) or in the presence of 100μM CoCl2 as a positive control.. Luciferase activity 
was determined with the luciferase assay system (Promega). All transfections were at 
least done in three separate culture dishes; data are expressed as means ± S.D. 
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Figure 3.5: Activation of adrenomeduline (ADM) expression by supernatant from 
Madurella mycetomatis strain 55 culture 
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HepG2 cells were incubated for 6 h under normoxic (21% O2) conditions in the presence 
of supernatant obtained from a culture of strain 55 Madurella mycetomatis grown in 
minimal media for 2 or 4 weeks. Total RNA was extracted, and cDNA was prepared 
from 1 µg total RNA using an oligo(dT) primer. For qualitative analysis, ADM forward 
primer 5'-CCCTGATGT TATTGGGTTCG-3' and reverse primer 5'-
TGGCGGTAGCGTTTGACT-3' with an amplification profile (33 cycles; 94°C for 
1 minute, 60 °C for 1 minute, and 72°C for 1.5 minutes). PCR for β-actin was performed 
by using forward primer 5'-CGG GAA ATC GTG CGT GAC AT-3' and reverse primer 
5'-GAA CTT TGG GGG ATG CTC GC-3' with an amplification profile (28 cycles; 94°C 
for 1 minute, 57°C for 1 minute, and 72°C for 1.5 minutes).  
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Figure 3.6: Activation of ADM expression by
Madurella mycetomatis  strain 14 culture supernatant
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HepG2 cells were incubated for 6 h under normoxic (21% O2) or hypoxic (3% O2) 
conditions in the presence of supernatant obtained from a culture of Madurella 
mycetomatis strain 14 (mm14) grown in minimal media for 2 (2W) or 4 weeks (4W) or in 
the presence of 100μM CoCl2 as a positive control. Total RNA was extracted, cDNA was 
prepared from 1 µg total RNA using an oligo(dT) primer , and subjected to real-time 
PCR for ADM and  β-actin quantification. ADM cDNA was normalized to β-actin cDNA 
and expressed as relative units × 1000. Bars represent mean cDNA values (± SD) from 
3 separate experiments in which each cDNA was quantitated in triplicate. 
Nox, p value = 0.000; Hox, p value = .003 
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Figure 3.7: Activation of VEGF expression by
Madurella mycetomatis  strain 14 culture supernatant
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HepG2 cells were incubated for 6 h under normoxic (21% O2) or hypoxic (3% O2) 
conditions in the presence of supernatant obtained from a culture of Madurella 
mycetomatis strain 14 (mm14) grown in minimal media for 2 (2W) or 4 weeks (4W) or in 
the presence of 100μM CoCl2 as a positive control. Total RNA was extracted, cDNA was 
prepared from 1 µg total RNA using an oligo(dT) primer , and subjected to real-time 
PCR for VEGF and  β-actin quantification. VEGF cDNA was normalized to β-actin 
cDNA and expressed as relative units × 1000. Bars represent mean cDNA values (± SD) 
from 3 separate experiments in which each cDNA was quantitated in triplicate. 
Nox, p value = 0.000; Hox, p value = .000 
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 Figure 3.8: Activation of ADM expression by
Madurella mycetomatis  strain 55 culture supernatant
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HepG2 cells were incubated for 6 h under normoxic (21% O2) condition in the presence 
of supernatant obtained from a culture of Madurella mycetomatis strain 55 (mm55) 
grown in minimal media for 2 (2W) or 4 weeks (4W) or in the presence of 100μM CoCl2 
as a positive control. Total RNA was extracted, cDNA was prepared from 1 µg total 
RNA using an oligo(dT) primer , and subjected to real-time PCR for ADM and  β-actin 
quantification. ADM cDNA was normalized to β-actin cDNA and expressed as relative 
units × 1000. Bars represent mean cDNA values (± SD) from 3 separate experiments in 
which each cDNA was quantitated in triplicate. 
p value = 0.002 
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Figure 3.9: Activation of VEGF expression by
Madurella mycetomatis  strain 55 culture supernatant
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HepG2 cells were incubated for 6 hours under normoxic (21% O2) condition in the 
presence of supernatant obtained from a culture of Madurella mycetomatis strain 55 
(mm55) grown in minimal media for 2 (2W) or 4 weeks (4W) or in the presence of 
100μM CoCl2 as a positive control. Total RNA was extracted, cDNA was prepared from 
1 µg total RNA using an oligo(dT) primer , and subjected to real-time PCR for VEGF 
and  β-actin quantification. VEGF cDNA was normalized to β-actin cDNA and expressed 
as relative units × 1000. Bars represent mean cDNA values (± SD) from 3 separate 
experiments in which each cDNA was quantitated in triplicate. 
p value = 0.001 
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 Figure 3.10: Effect of dexamethazone on the fungal-
induced VEGF secretion by HepG2 cells
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HepG2 cells were incubated for 6 hours under normoxic (21% O2) or hypoxic (3% O2) 
condition in the presence of supernatant obtained from a culture of Madurella 
mycetomatis strain 14 (mm14) and strain 55 (mm55) grown in minimal media for 4 
weeks (4W) or in the presence of 100μM CoCl2 as a positive control and in the presence 
of 100 nM dexamethasone. VEGF level was measured in Hep G2 culture supernatants 
using ELISA. 
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Table 3.2: Expression of ADM mRNA by HepG2 cells under the effect of strain 14 
culture supernatant 
 
 
Normoxia (21% O2)    
  Strain 14, 2 Weeks Strain 14, 4 
Weeks 
  25.7 ± 4.39 33.6 ± 3.20 
 Negative Control 
 1.2 ± 0.18 p = 0.001109 p = 0.0001580 
 Positive Control 
 39.5 ± 7.90 p = 0.031408 p = 0.474134 
Hypoxia (3% O2)    
  Strain 14, 2 Weeks Strain 14, 4 
Weeks 
  103.9 ± 9.93 89.0 ± 5.7 
 Negative Control 
 36.0 ± 9.93 p = 0.007462 p = 0.028586 
 Positive Control 
 118.0  12.08 p = 0.775436 p = 0.274119 ±
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Table 3.3: Expression of VEGF mRNA by HepG2 cells under the effect of strain 14 
culture supernatant 
 
 
Normoxia (21% O2)    
  Strain 14, 2 Weeks Strain 14, 4 Weeks 
  8.3 ± 1.01 10.0 ± 2.34 
 Negative Control 
 0.2 ± 0.14 p = 0.000798 p = 0.000203 
 Positive Control 
 10.9 ± 1.62 p = 0.220169 p = 0.88923 
Hypoxia (3% O2)    
  Strain 14, 2 Weeks Strain 14, 4 Weeks 
  57.8 ± 10.27 61.0 ± 14.15 
 Negative Control 
 9.9 ± 0.97 p = 0.000764 p = 0.000495 
 Positive Control 
 55.6  3.09 p = 0.990010 p = 0.881949 ±
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Table 3.4: Expression of ADM mRNA by HepG2 cells under the effect of strain 55 
culture supernatant 
 
Normoxia 
(21% O2) 
   
  Strain 55, 2 Weeks Strain 55, 4 Weeks 
  32.0 ± 3.98 26.9 ± 7.51 
 Negative Control 
 10.2 ± 1.55 p = 0.002774 p = 0.013345 
 Positive Control 
 30.98  4.76 p = 0.993453 p = 0.751822 ±
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Table 3.5: Expression of VEGF mRNA by HepG2 cells under the effect of strain 55 
culture supernatant 
 
Normoxia 
(21% OB2) 
   
  Strain 55, 2 Weeks Strain 55, 4 Weeks 
  81.1 ± 49.64 193.4 ± 31.73 
 Negative Control 
 9.2 ± 1.39 p = 0.154904 p = 0.001246 
 Positive Control 
 184.7  43.89 p = 0.0351760 p = 0.990780 ±
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Chapter Four 
Discussion 
4:. DISCUSSION 
Based on the observation that the microcirculation in the eumycetoma lesion has close 
similarities with that of malignant tumors in spite of absence of ischemic changes in the 
lesion343 and the recent isolation of a number of fungal products that are capable of in 
vitro accumulation of the transcriptional factor HIF-1346, we became interested in 
exploring the role of the fungus in the development of the microcirculation in the 
eumycetoma lesion. This unprecedented work elucidate a novel mechanism of 
angiogenesis associated with a fungal infection and provide an evidence for the positive 
role of Madurella mycetomatis in the escalation of the pathologic microcirculation 
previously observed in the eumycetoma lesion. 
In this study immunhistochemical analysis using monoclonal mouse anti-human CD31 
was performed to appraise the vascularity of the eumycetoma lesion in 23 patients who 
were previously diagnosed as positive for Madurella mycetomatis. The vessel density in 
the center of the lesion where fungal grains are abundant was compared with that in a 
grain-free tissue taken from the lesion periphery. The vessel count was found to be higher 
in the center of the lesion compared with that in the periphery (17.8± 8.10, 12.6± 6.29; p 
= 0.008, n=23). This result is in accord with the previous studies on the vascularity of 
eumycetoma lesion and with other studies on solid tumors and chronic inflammatory 
conditions. 
Immunohistochemical analysis was used to gauge the accumulation of HIF-1α in the 
eumycetoma lesion in 23 patients previously diagnosed with eumycetoma caused by 
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Madurella mycetomatis. HIF-1α was detected in all sections taken from center of the 
lesion as well as those form the periphery. We demonstrated that HIF-1α is 
overexpressed in the lesion center, where fungal grains are abundant, as evident by the 
higher count of HIF-1α positively stained cells. HIF-1α positive cell count did not 
correlate with the duration neither with the size of the lesion. Previous 
immunohistochemical studies of HIF-1 demonstrated that there are detectable levels of 
HIF-1α protein in benign tumors, elevated levels in primary malignant tumors, and a 
marked amount in tumor metastases, in contrast to its absence in normal tissues6, 152. In 
contrary to previous studies held on malignant solid tumors where immunohistochemical 
detection of HIF-1α demonstrated patterns of expression with typical perinecrotic 
staining at the hypoxic tumor margin at a distance from blood vessels152, 352, 353, 354, this 
study demonstrated that within the eumycetoma lesion HIF-1α was overexpressed by 
cells surrounding or near the capillaries in areas that showed no evidence of hypoxia, but 
whether the distribution of HIF-1α in the eumycetoma lesion correlates with the fungus 
density need further investigations. Studies on malignant tumors have provided evidences 
for the upregulation of HIF-1 via both oxygen dependent and independent factors, 
including oncogenes155, 156, 157, 355, 356, 357, growth factors and cytokines83, 91, 158, 358, 359, and 
reactive oxygen species159. In eumycetoma the amassing of HIF-1α positive cells near 
vascularized areas of the lesion denotes dominance of an oxygen independent 
upregulatory mechanism of HIF-1α. This raised our speculations for a role for the fungal 
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products in the upregulation of HIF-1α which may be reinforced by the up regulatory 
effect of inflammatory cytokines.  
We further investigated the level of HIF-1α mRNA in the eumycetoma lesion. We used 
reverse transcriptase quantitative real time PCR to compare the expression of HIF-1α 
mRNA in the lesion center and the lesion periphery. HIF-1α mRNA was found to be 
significantly higher in the lesion center but there was no correlation between the level of 
HIF-1α mRNA and HIF-1α positive cell count. These findings denoted that accumulation 
of HIF-1α in the eumycetoma lesion was in part due to upregulation of the transcription 
of HIF-1α mRNA and in part due stabilization of HIF-1α protein as evident by the lack of 
correlation between HIF-1α mRNA level and HIF-1α positive cell count. This is 
comparable to the accummulation of HIF-1α in malignant tumors where both 
transcriptional360 and posttranscriptional37 modifications of HIF-1α contribute to its 
accumulation. However, the exact mechanisms responsible for HIF-1α accumulation in 
eumycetoma lesion remain to be elucidated. 
In order to investigate the transcriptional activity of HIF-1 and its role in the angiogenesis 
in the mycetoma lesion, we quantified the mRNA of VEGF and ADM which are well 
documented proangiogenic factors regulated by HIF-1. VEGF and ADM mRNA were 
measured in grain rich tissue specimens taken from the lesion center and in grain free 
specimens taken from the periphery of the lesion. The levels of VEGF and ADM mRNA 
were normalized to the level of the house keeping gene β actin. The levels of both VEGF 
and ADM mRNA were found to be significantly higher in the grain rich tissue towards 
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the center of the lesion compared with the grain free tissue. The increase in the level of 
ADM mRNA in the grain rich tissue was more prominent than that of VEGF mRNA. 
These findings assert a positive cooperative role of VEGF and ADM in the 
hypervascularity of the mycetoma lesion. Such cooperative angiogenic activity between 
VEGF and ADM was previously reported in tumors such as uterine leiomyoma361 and 
pancreatic adenocarcinoma362. Previous studies asserted the attendance of VEGF in many 
other inflammatory conditions including rheumatoid arthritis363, 364, inflammatory bowel 
disease365, 366, 367, psoriasis368, 369, 370. and collagenous colitis371. Besides it proangiogenic 
activity, chronic overexposure to VEGF was reported as an upregulator of vascular cell 
adhesion molecule 1 (VCAM-1), beta1- and beta2-integrins, and intercellular adhesion 
molecule-1 (ICAM-1) and major histocompatibility complex (MHC) class I and II372, 373, 
374. The expression of VEGF in the eumycetoma lesion may be implicated in the 
recruitment of immune cells and modulation of the immune response to the infection. 
In a previous study using knockdown of HIF-1 through small interfering RNA in a DLD-
1 colon cancer cell xenograft confirmed that HIF-1 was not the only factor regulating 
angiogenesis in solid tumors375, 376. Several studies had focused on the HIF-1–
independent regulatory factors of VEGF. c-Myc oncogene377, 378, RAS oncogene316, and 
the transcriptional factors nuclear factor-κB (NF-κB)379, 380, 381 were documented in 
different studies as a HIF-1–independent upregulators of VEGF. Whether the induction 
of VEGF and ADM expression in the eumycetoma lesion is exclusively due to the 
increased HIF-1 activity or contributed by other factors remains a question for further 
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study. However, the lack of correlation between VEGF and ADM mRNA expression and 
HIF-1 accumulation may raise speculations on other HIF-1 independent mechanism 
contributing to the upregulation of VEGF and ADM in the eumycetoma lesion. 
Several studies have indicated that angiogenic activators play an important part in the 
growth and spread of tumors. On immunohistochemical examination, the VEGF and its 
receptors were found to be expressed in a number of human cancers382. These factors are 
known to affect the prognosis of adenocarcinomas of the uterine cervix383, 
endometrium384, ovary385, and stomach386. Besides, a significant correlation between the 
expression of VEGF and prognosis has been described in colorectal cancer387, lung 
cancer388, breast cancer389, 390, head and neck squamous cell carcinoma391, Kaposi 
sarcoma392, and malignant mesothelioma393. These studies also indicated that the levels of 
angiogenic factors had predictive value in the identification of the patients with poor 
prognosis. In addition, several studies of different types of cancer reported that HIF-1α 
had been associated with an unfavorable prognosis in patients with a wide range of 
malignant tumors. Immunohistochemical analyses revealed that HIF-1α was 
overexpressed in many human cancers152. In oligodendroma394, breast395, 396, ovary397, 398, 
399, cervix400, 401, lung402, colon403, and head and neck cancers404, 405, 406, 407, 408, 409, 410 an 
obvious correlation between HIF-1α overexpression and a poor outcome has been 
described. In contrast, HIF-1 overexpression was a favourable independent prognostic 
factor in renal cell carcinoma (RCC)411 and non-small cell lung cancer412, although this 
finding was disproved by another study of non-small cell lung cancer413. HIF-1 
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expression also confered resistance to radiation therapy and to chemotherapy404, 407, 414, 415, 
416. In spite of the in vitro susceptibility of the eumycetoma causative agents to antifungal 
agents, such as ketoconazole and itraconazole417, but clinical trials proved that  response 
to antifungal agents was often poor and aggressive surgical excision remained the 
mainstay in the management of eumycetoma418. This is similar to solid tumors where 
tumor cells that are sensitive to chemotherapy agents in vitro often had been identified as 
resistant or have become resistant to chemotherapy in vivo. Studies on solid tumors have 
revealed that VEGF contribute to tumor resistance to chemotherapy via both intracellular 
mechanisms (e.g., multidrug-resistant genes, drug export pumps, alterations in metabolic 
pathways, gene mutations) and factors within the tumor microenvironment419, 420, 421. The 
disconnect between in vitro and in vivo fungal response may be analogized to the 
response of the tumor cells where resistance to chemotherapy is at least in part accredited 
with the lesion microenvironment and its effect on the delivery of chemotherapeutic 
agents to its target cells. VEGF has been shown to increase potently the permeability of 
endothelium; it is 50,000 times more potent than histamine in increasing the permeability 
of vascular endothelium422. The increased expression of VEGF within the mycetoma 
lesion could possibly lead to formation of vasculature with high permeability and leads to 
regions of increased interstitial fluid pressure. During the loss of normal oncotic and 
hydrostatic pressure gradients in the leaky vessels, the resultant interstitial hypertension 
would become a barrier to movement of therapeutic agents into the interstitial space. This 
barrier would prevent therapeutic agents from reaching their targets within the lesion. 
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However, the prognostic value of the microvascular density and HIF-1 expression in the 
eumycetoma lesion and their implication in the low curative rate of antifungal agents 
await to be explored before any therapeutic approach targeting HIF-1 or VEGF in the 
eumycetoma lesion. 
To answer the question of whether fungal products are involved in the upregulation of 
HIF-1α and its descendant genes, we scrutinized the effect of supernatants obtained from 
the culture of two pathogenic strains of Madurell mycetomatis, namely strain 14 and 
strain 55, on the accumulation HIF-1α and the expression of its down stream genes in 
HepG2 cells. Western blot analysis of HIF-1α revealed an unequivocal evidence for the 
upregulation of HIF-1α in HepG2 cells when treated with supernatants obtained from the 
cultures of both strain 14 and strain 55 under both normoxic and hypoxic conditions. This 
fungal-induced upregulation of HIF-1α was only seen when the fungus was grown in 
minimal media while supernatant obtained from fungal culture in RPMI fail to induce 
any effect on HIF-1α expression. These findings indicated that the ability of the fungal 
supernatant to induce HIF-1α was dependent on the fungus culture conditions which need 
further studies to be well defined. Several fungal products, including Pycnidione and 8-
methyl-pyridoxatin, that are capable of in vitro induction of HIF-1 have been previously 
isolated from non pathogenic fungi. Pathogen-induced upregulation of HIF-1 was 
previously described in bacterial infection caused by Chlamydia pneumoniae423, Yersinia 
enterocolitica424, Pseudomonas aeruginosa425, Bartonella henselae426, Staphylococcus 
aureus427, and Mycobacterium tuberculosis428. In this study we elucidated a role of 
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fungal-induced HIF-1 activity in the pathogenesis of a fungal infection. The mechanism 
responsible for the increased expression of HIF-1α by Madurella mycetomatis fungal 
supernatants is not clearly understood. Different pathogens have evolved a variety of 
mechanisms through which they can induce HIF-1α. In Mycobacterium tuberculosis, 
secretion of iron chelating agents interferes with prolyl hydroxylase preventing HIF-1α -
VHL interaction and diverts HIF-1α away from ubiquitination, such mechanism directed 
towards acquisition of iron is also seen in non pathogenic fungi activating HIF-1. 
However, the mechanism involved in the induction of HIF-1α by Escherichia coli LPS is 
at least in part mediated via decreasing prolyl hydroxylase mRNA production in a TLR4-
dependent fashion429, 430 and in part via promotion of HIF-1α mRNA expression431, 432. 
The wide scope through which microbial pathogens and non pathogenic fungi affect HIF-
1α expression necessities further exploration of the mechanisms involved in the induction 
of HIF-1α. However, it seems that the in vivo induction of HIF-1α by culture 
supernatants is merely due to stabilization HIF-1α protein since we didn’t observe any 
increase in the expression of HIF-1α mRNA in HepG2 cells when treated with Madurella 
mycetomatis culture supernatant. Furthermore, we here hypothesize two candidate 
molecules to be responsible for the induction of HIF-1α by Madurella mycetomatis: the 
first is melanin and the second is a yet unwell characterized siderophore. Melanin 
pigments are multifunctional polymers found in all biological kingdoms. They are 
negatively charged, hydrophobic macromolecules of high molecular weight synthesized 
by the oxidative polymerization of phenolic and/or indolic compounds433. Several types 
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of melanins have been described in bacteria, plants, animals, and fungi: eumelanins, 
phaeomelanins, allomelanins, and pyomelanins. Eumelanins are formed from quinines 
and free radicals. Phaeomelanins are derived from tyrosine and cysteine. Allomelanins 
are synthesized from nitrogen-free precursors, and pyomelanins are derived from the 
catabolism of tyrosine via p-hydroxyphenylpyruvate and homogentisic acid (HGA)433, 434. 
Madurella mycetomatis: produces melanin both in vivo and in vitro when grown in 
minimal media but not in RPMI media435. The melanins synthesized by Madurella 
mycetomatis and their synthetic pathway are not yet well characterized, but they are 
likely to be of the phaeomelanins and pyomelanins types435. Due to their electrochemical 
properties, melanins may act both as an electron donor and electron acceptor436, 437. 
Therefore, they are not only an effective free radical sweepers, but also an ion-exchange 
resin able to bind iron ions438 . These physicochemical properties of melanin raised our 
speculations that melanin could possibly be responsible for the Madurella mycetomatis-
induced HIF-1 expression. This postulation has been reinforced by our finding that 
supernatants obtained from Madurella mycetomatis culture in RPMI media, where 
melanin production by the fungus is halted, failed to induce HIF-1α expression. The 
second candidate molecule which may contribute to the induction of HIF-1α by 
Madurella mycetomatis might be a siderophore. Siderophores are low molecular weight 
iron chelators secreted by the fungi and bacteria under iron-starved conditions as part of a 
thievery mechanism for iron acquisition from the surrounding environment439. Iron 
chelation by the fungal siderophore could possibly bind available iron, act as prolyl 
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hydroxylase inhibitor and prevent prolyl hydroxylation and ubiquitination of HIF-1α. 
This hypothesis is supported by a previous study using chrome azurol S blue plates 
constituted with yeast morphology agar (CAS-YMA) siderophores of the hydoxamate 
type were detected in the culture media of Madurella mycetomatis440. Among the 
hydroxamate siderophore previously isolated from other microorganisms culture broth (e. 
g. Streptomyces sp.) which are well known for their induction of HIF-1α is 
desferoxamine B349, 441, 442, 443, 444. The effects of Madurella mycetomatis siderophore on 
HIF-1α induction might be similar and comparable to that of desferoxamine. 
The effect of Madurella mycetomatis products on the nuclear activity of HIF-1 and its 
DNA binding was demonstrated by the reporter gene assay using transiently transfected 
HepG2 cells with HRE-driven luciferase gene. Our results showed that Madurella 
mycetomatis products have the capability to increase the transcriptional activity of HIF-1 
under both normoxic and hypoxic conditions. The effect of Madurella mycetomatis 
products was only demonstrated when the fungus was grown in minimal media. These 
findings entirely comply with the result from the western blot experiment. The 
effectiveness of the Madurelal mycetomatis products on HIF-1 induction seems to be 
dependent on the strain and the fungus culture conditions, as evident by the failure of the 
two weeks old culture supernatants of strain 55 in the induction of HIF-1 in contrary to 
the induction of HIF-1 by supernatants obtained from four weeks old culture supernatants 
of the same strain and induction of HIF-1 by the two and four weeks old culture 
supernatants of strain 14. 
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We further investigate the effect of Madurella mycetomatis products on the expression of 
VEGF and ADM mRNA. Strain 14 products were capable of increasing the expression of 
both VEGF and ADM mRNA under both normoxic and hypoxic conditions. The effect of 
strain 14 products was more discernible on the expression of VEGF mRNA especially 
under hypoxic conditions and seems to be affected by the age of the fungus culture. The 
effect of strain 14 products on ADM mRNA expression was paradoxically less 
perceptible with the four weeks old culture supernatant when tested under hypoxic 
conditions. Strain 55 products were only tested under normoxic conditions where it 
showed a significant increase in the expression of both VEGF and ADM mRNA. Here 
again the effect on VEGF mRNA expression is more perceptible and it correlates with the 
age of the fungus culture while the effect on ADM mRNA was less prominent when 
using four week old fungal supernatants. These results are generally in concert with the 
high level of VEGF and ADM mRNA seen in mycetoma lesion and they provide an 
evidence for the presence of Madurelal mycetomatis secreted product that promotes 
angiogenesis. The incongruence between the in vitro and in vivo discrete quantitative 
expression of VEGF and ADM mRNA suggests attendance of yet unestablished factors 
governing secretion of a proangiogenic substance by Madurella mycetomatis strains and 
a subjoining participation of factors that determine human cell responsiveness to that 
substance. 
In order to confirm secretion of VEGF by hepG2 cells under the effect of Madurella 
mycetomatis culture supernatants, we investigated the level of VEGF in supernatants 
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obtained from HepG2 treated with fungus culture supernatants. This experiment provided 
an unambiguous evidence for the fungal-induced VEGF secretion by HepG2 under the 
effect of supernatants obtained from strain 14 cultures. But the effect of strain 55 culture 
supernatants was statistically insignificant. We hypothesize that the fungal-induced 
VEGF secretion may occur in vitro and contribute to the pathologic microvascular 
circulation seen in the eumycetoma lesion. 
We further investigated the effect dexamethasone on the Madurella mycetomatis culture 
supernatants-induced secretion of VEGF by HepG2 cells. Dexamethasone (100 nM) 
completely blunted the effect of Madurella mycetomatis culture supernatants on VEGF 
secretion. In a previous study dexamethasone exerted an inhibitory effect on VEGF 
secretion and reduced VEGF mRNA level in cultures of tibial growth plate chondrocytes 
of neonatal piglets445. In contarary another study using HeLa cells documented a 
synergistic effect of dexamethasone and hypoxia on the expression of VEGF. In vivo 
studies provided evidence for an antiangiogenic effect of dexamethasone446, 447. Recent 
studies provided distinct evidence for the inhibitory action of dexamethasone on VEGF 
expression448, 449, 450. Our findings are in concert with the recent evidences supporting the 
inhibitory effect of dexamethasn on VEGF expression. The therapeutic value of the 
inhibitory effect of dexamethasone on Madurella mycetomatis induced VEGF secretion 
need be thouroughly investigated. 
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CONCLUSIONS AND RECOMMENDATIONS 
This study concludes that HIF-1 and its down stream genes products, VEGF and ADM, 
are attendant in the development of the microcirculation in the mycetoma lesion caused 
by Madurella mycetomatis. The high concentration of HIF-1 in the lesion is in part due to 
increased transcription of HIF-1α mRNA and in part due to increased stability of HIF-1α. 
The stability of HIF-1α is at least partly due to a yet unidentified factor produced by 
Madurella mycetomatis. The exact nature of the fungal product responsible for the in 
vivo and in vitro induction of HIF-1 and its downstream genes need be further 
investigated. 
The prognostic value of the microvascular density and HIF-1 expression in the 
eumycetoma lesion and their implication in the low curative rate of antifungal agents 
need be more explored before any therapeutic approach targeting HIF-1 or VEGF in the 
eumycetoma lesion. 
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